CN110582206A - Purposefully selected compositions comprising purified cannabinoids and/or purified terpenes - Google Patents

Abstract

disclosed herein is a novel composition comprising a purified cannabinoid and a purified terpene. In one embodiment, the composition comprises one or more purified cannabinoids. In one embodiment, the composition comprises a combination of one or more purified cannabinoids and one or more purified terpenes. In one embodiment, the composition comprises a non-naturally occurring proportion. In one embodiment, the composition comprises a non-naturally occurring concentration. In one embodiment, the composition comprises an unexpected and/or synergistic effect.

Description

A purposefully selected group comprising purified cannabinoids and/or purified terpenes compound

technical field

This disclosure relates to the cannabis industry. In particular, the present disclosure relates to compositions and formulations comprising novel, purposefully engineered combinations of purified compounds.

Background technique

The term "cannabis" refers to the genus of flowering plants. The Cannabis genus includes several species, including Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Hemp has long been used for hemp fiber, for seeds and seed oil, for medicinal purposes, and as a recreational drug.

According to some reports, cannabis consists of at least 483 known compounds including cannabinoids, terpenoids, flavonoids, nitrogenous compounds, amino acids, proteins, glycoproteins, enzymes, sugars and related compounds, hydrocarbons, alcohols compounds, aldehydes, ketones, acids, fatty acids, esters, lactones, steroids, terpenes, non-cannabinoid phenols, vitamins and pigments.

Cannabinoids are of particular interest in research and commercialization. Most extractions of cannabis plant matter are aimed at extracting cannabinoids, specifically tetrahydrocannabinol (THC). THC can be used to relieve pain, treat glaucoma, and relieve nausea. THC is also gaining popularity as a recreational drug. Typically, cannabinoids are extracted from the cannabis plant as part of a crude blend, combined with other compounds found in the cannabis plant.

Although progress has been made in isolating the small amounts of cannabinoids and terpenes found in the cannabis plant, no work has been done in formulating compositions with specific combinations of these compounds in purified or isolated form. Some of the less common cannabinoids were neither isolated nor studied individually or in any combination. Additionally, there has been little or no work to develop compositions with purposefully designed, reproducible, consistent and reliable ratios of purified cannabinoids. In particular, there is no research and development on the combination of cannabinoids and purified terpenes.

There is a need for new synthetic compositions comprising purified cannabis components. In particular, there is a need for compositions comprising novel combinations of at least one cannabinoid and at least one purified terpene.

SUMMARY OF THE INVENTION

Disclosed herein are novel compositions comprising purified cannabinoids and/or purified terpenes. In one embodiment of the present disclosure, the composition comprises a first purified cannabinoid and a first purified terpene. In one embodiment of the present disclosure, the composition comprises a first purified cannabinoid and a second purified cannabinoid. In one embodiment of the present disclosure, the composition comprises a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene. In one embodiment of the present disclosure, the composition comprises a first purified cannabinoid, a first purified terpene, and a second purified terpene.

The compositions disclosed herein are purposefully formulated to provide artificial, non-naturally occurring combinations, concentrations and/or ratios of compounds sometimes found in naturally occurring cannabis plants.

In one embodiment, the compositions disclosed herein include a first purified cannabinoid and a first purified terpene in non-naturally occurring proportions. In one embodiment, the compositions disclosed herein include a non-naturally occurring concentration of a first purified cannabinoid and a first purified terpene.

In one embodiment, the compositions disclosed herein include a first purified cannabinoid and a second purified cannabinoid in non-naturally occurring proportions. In one embodiment, the compositions disclosed herein include a non-naturally occurring concentration of a first purified cannabinoid and a second purified cannabinoid.

In one embodiment, the compositions disclosed herein include non-naturally occurring proportions of a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene. In one embodiment, the compositions disclosed herein include a non-naturally occurring concentration of a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene.

In one embodiment, the compositions disclosed herein include non-naturally occurring proportions of a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid. In one embodiment, the compositions disclosed herein include non-naturally occurring concentrations of a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid.

In one embodiment, the compositions disclosed herein include a first purified terpene, a second purified terpene, and a first purified cannabinoid in non-naturally occurring proportions. In one embodiment, the compositions disclosed herein include non-naturally occurring concentrations of the first purified terpene, the second purified terpene, and the first purified cannabinoid.

In one embodiment of the present disclosure, the composition comprises a non-naturally occurring ratio of purified cannabinoids to purified terpenes of 10:1 to 1:1.

In one embodiment of the present disclosure, the composition comprises a non-naturally occurring ratio of purified cannabinoids to purified terpenes of 10:1 to 5:1.

In one embodiment of the present disclosure, the composition comprises a non-naturally occurring ratio of purified cannabinoids to purified terpenes of greater than 10:1.

Disclosed herein are compositions comprising:

the first purified cannabinoid; and

a compound selected from the second purified cannabinoid or the first purified terpene,

wherein the composition is substantially free of cellulose.

As used in the context of this application, the term "purified" means extracted, isolated and/or separated from other compounds, preparations, compositions, substances and/or masses. In one embodiment, the term "purified" refers to cannabinoids that have been separated from the plant matter from which they are derived.

In one embodiment, the term "purified" refers to a cannabinoid ("purified cannabinoid") that is separated from other cannabinoids present in the plant matter from which it is derived. In one embodiment, the term "purified" refers to cannabinoids ("purified cannabinoids") separated from the terpenes present in the plant matter from which they are derived. In one embodiment, the term "purified" refers to a cannabinoid ("purified cannabinoid") that is separated from secondary compounds present in the plant material from which it is derived. In one embodiment, the term "purified" refers to cannabinoids ("purified cannabinoids") that are separated from all substances present in the plant matter from which they are derived.

In one embodiment, the term "purified" refers to terpenes ("purified terpenes") that are separated from other cannabinoids present in the plant matter from which they are derived. In one embodiment, the term "purified" refers to terpenes ("purified terpenes") that are separated from terpenes present in the plant matter from which they are derived. In one embodiment, the term "purified" refers to terpenes ("purified terpenes") that are separated from secondary compounds present in the plant matter from which they are derived. In one embodiment, the term "purified" refers to terpenes ("purified terpenes") that are separated from all substances present in the plant matter from which they are derived.

In the context of the present disclosure, purified compounds can be purposefully formulated with other compounds at various levels of purity. For example, depending on the desired result, when a particular cannabinoid or terpene is 60-65% pure, 65-70% pure, 70-75% pure, 75-80% pure, 80-85% pure, 85-90% pure % pure, 90-95% pure, 95-99% pure, 99-99.9% pure, 99.9+%, or greater than 99% pure, can be formulated with other molecules. If ingredients for purposeful formulation are purified prior to said purposeful formulation, then the act of subsequently formulating them does render them not "purified" within the scope of the ingredient list.

In one embodiment, purified means "substantially free" of other substances, such as compounds, particles, nutrients, plant-derived substances, solvents, and the like. In one example, the term "purified" refers to a compound purified from a crude extract. For example, biologically derived substances or BDS, resulting in significant differences between purified compounds and extracts. In one embodiment, substantially free means that the compound contains no (or insignificant amounts) other substances.

In the context of the present disclosure, the term "plant" refers to whole plants and plant parts such as leaves, roots, bark, flowers, and the like. The term plant also includes dried plants and dried parts of plants.

Within the scope of this disclosure, where a compound contains a stereocenter, the term "purified" includes isolated stereoisomers and also includes mixtures of stereoisomers, provided that the compound having a stereoisomer does not contain a different atom Connectivity to other compounds.

As used in the context of this application, the term "man-made" means designed or purposefully created by humans, as opposed to being "natural" in nature without human influence. In one embodiment, a man-made composition is a formulation prepared by combining naturally occurring molecules in new, non-natural ways, such as by isolating individual chemical components of a plant and then recombining some of these components to achieve these components different concentrations and/or ratios. In one embodiment, an artificial composition is a formulation prepared by one or more methods in a chemical extraction and purification laboratory.

The properties of the compositions of the present disclosure - made by purposefully combining purified compounds in concentrations, combinations and/or ratios - differ from preexisting technologies such as extracts or other processed materials such as biopharmaceuticals, Medical grade plant extracts, etc.

In one embodiment, purification includes the use of various solvents such as ethanol, butane, methane, carbon dioxide, ice, water, steam. In one embodiment, purification includes various techniques, such as chromatography, crystallization, filtration, centrifugation, etc., or various combinations of such techniques. In one embodiment, purification includes extracting cannabinoids and other plant molecules from cultivated plants to express the desired cannabinoid and/or terpene profile to achieve purity.

As used herein, the term "cellulose" refers to an organic compound having the _formula ( _{C6H10O5 ) n} . In one embodiment, the phrase "substantially free of cellulose" is intended to distinguish purified components of naturally occurring plants (eg, cannabis plants) from isolated compounds (eg, cellulose) that are free of plant material.

As used herein, the term "naturally occurring" means naturally occurring, produced, occurring or synthesized. In one embodiment, naturally occurring refers to secondary compounds that are synthesized in plants. In one embodiment, naturally occurring refers to the collection of cannabinoids synthesized in Cannabis plants. In one embodiment, naturally occurring refers to the concentration of the compound in the plant. In one embodiment, naturally occurring refers to the concentration of cannabinoids in a Cannabis plant. In one embodiment, naturally occurring refers to the proportion of secondary compounds in a plant. In one embodiment, naturally occurring refers to the ratio of the first cannabinoid to the second cannabinoid in a Cannabis plant.

As used herein, the term "naturally occurring ratio" refers to the ratio of one or more compounds relative to another compound or compounds in a Cannabis plant. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of cannabinoid in the Cannabis plant. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpenes in the Cannabis plant. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpenes in the Cannabis flower. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpenes in the genus extract. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpene in the formulation prepared from the Cannabis plant extract.

In one embodiment, naturally occurring ratios are expressed as molar ratios. In one embodiment, the naturally occurring ratio is expressed as mass. In one embodiment, the mass and/or molar ratio is measured by chromatography and/or spectroscopy.

As used herein, the term "non-naturally occurring ratio" refers to the ratio of one or more compounds relative to another compound or compounds in a composition produced by a human. In one embodiment, the non-naturally occurring ratio is the amount of cannabinoids relative to terpenes and is not observed in Cannabis plants. In one embodiment, the non-naturally occurring proportions are expressed as molar ratios. In one embodiment, the non-naturally occurring proportions are expressed as mass. In one embodiment, the mass and/or molar ratio is measured by chromatography and/or spectroscopy.

In one embodiment, the non-naturally occurring ratio is the amount of cannabinoid relative to the amount of terpenes in a human-formulated composition not observed in Cannabis plants. In one embodiment, the non-naturally occurring ratio is the amount of the cannabinoid relative to the amount of the second cannabinoid in the human-formulated composition not observed in the Cannabis genus.

As used herein, the term "naturally occurring concentration" refers to the amount of one or more compounds relative to the entire naturally occurring reference sample. In one embodiment, the naturally occurring concentration is the amount of cannabinoid in the Cannabis sample. In one embodiment, the naturally occurring concentration is the amount of cannabinoid in the dried or cured flower of the Cannabis genus. In one embodiment, the naturally occurring concentration is the amount of cannabinoids in the crude extract of the Cannabis plant.

In one embodiment, the naturally occurring concentration is the amount of terpenes in the Cannabis sample. In one embodiment, the naturally occurring concentration is the amount of terpenes in dried or cured flowers of the Cannabis plant. In one embodiment, the naturally occurring concentration is the amount of terpenes in the crude extract of the Cannabis plant. In one embodiment, the non-naturally occurring concentration is measured molar and expressed as molarity. In one embodiment, the naturally occurring concentration is measured by mass percent.

As used herein, the term "non-naturally occurring concentration" refers to the amount of one or more compounds relative to the entire sample in the artificial composition. In one embodiment, the non-naturally occurring concentration is the amount of cannabinoid relative to the total composition. In one embodiment, the non-naturally occurring concentration is the amount of terpene relative to the total composition. In one embodiment, the non-naturally occurring concentration is measured molar and expressed as molarity. In one embodiment, the non-naturally occurring concentration is measured by mass percent.

As used herein, the term "total mass" refers to the total mass of a given reference sample. In one embodiment, the total mass is measured by molecular weight.

The term "pharmacological fingerprint" refers to a collection of data on the activity of a single cannabinoid or terpenes, or any combination of cannabinoids and/or terpenes, at one or more targets in the human body, eg, cannabinoid receptors , for example, CB1, CB2, GPR55, 5HT-1A, 5HT-2A, TRPV1, serotonin receptors or mu-opioid receptors. The compositions disclosed herein are generated using cellular (eg, pharmacological fingerprints) and/or clinical data to select and combine specific combinations of compounds with novel properties.

As used herein, the term "efficacy" refers to the efficacy, effect, activity, or effectiveness of a composition disclosed herein at a particular cellular receptor. In one embodiment, efficacy is measured by the subject's response. In one embodiment, potency is measured by the cellular responsiveness of cannabinoids to receptors, such as CB1, CB2, GPR55, 5HT-1A, 5HT-2A, TRPV1, serotonin receptors or mu-opioid receptors. In one embodiment, efficacy refers to EC50. In one embodiment, potency refers to the magnitude of the response.

As used herein, the term "agonist" refers to the action of a compound, agonist, that activates a receptor and induces a response. In one embodiment, the receptor is selected from CB1, CB2, GPR55, 5HT-1A, 5HT-2A, TRPV1, a serotonin receptor or a μ-opioid receptor. In one embodiment, the agonist is a cannabinoid. In one embodiment, the agonist is a terpene.

As used herein, the term "antagonistic" refers to a combination of two or more compounds that have an effect. In one embodiment, antagonism is a composition comprising a cannabinoid that affects another cannabinoid, ie, a cannabinoid that affects the binding of another cannabinoid to a receptor. In one embodiment, the antagonist is a composition comprising a terpene that affects another cannabinoid, ie, a terpene that affects the binding of another cannabinoid to a receptor.

In one embodiment, the compositions disclosed herein alter the potency of endogenous neurotransmitters, eg, serotonin receptors, adrenergic receptors, dopamine receptors, GABAergic receptors, glutamatergic receptors, in an organism , histaminergic receptors, cholinergic receptors, opioid receptors, glycinergic receptors, etc., on one or more of their endogenous receptors, e.g., serotonin, norepinephrine, epinephrine, dopamine etc.

In one embodiment, the compositions disclosed herein increase the potency of serotonin at the 5-HT _1A receptor. In one embodiment, the compositions disclosed herein increase the potency of serotonin at the 5-HT _2A receptor. In one embodiment, the compositions disclosed herein increase the potency of serotonin at the 5-HT _1A receptor and decrease the potency of serotonin at the 5-HT _2A receptor. In one embodiment, the compositions disclosed herein decrease the potency of serotonin at the 5-HT _1A receptor and increase the potency of serotonin at the 5-HT _2A receptor.

For example, formulations of the present disclosure are achieved by expressing human components of the endocannabinoid system (or other known targets of cannabis pharmacology) in cultured cells and treating the cells with serial dilutions of individual compounds or combinations of compounds To determine the individual EC50 of each component for each target, and whether the addition of other components would alter the magnitude of the response or the effective concentration (EC50) of the response.

As used herein, the term "EC50" means "half-maximal effective concentration," which refers to the amount of a formulation (eg, a cannabinoid, terpene, or a combination thereof) that induces a response halfway between baseline and maximum after a specified exposure time. concentration. In one embodiment, the EC50 value is used as a measure of drug efficacy.

The EC50 of a graded dose-response curve represents the concentration of the compound at which 50% of its maximal effect is observed. The EC50 of a quantum dose-response curve represents the concentration of compound at which 50% of the population exhibits a response after a specified exposure duration.

As used herein, the term "response magnitude" refers to the magnitude of the responsiveness to the compositions disclosed herein. In one embodiment, the magnitude of the response is the response of a receptor, eg, CB1, CB2, GPR55, 5HT-1A, 5HT-2A, TRPV1, a serotonin receptor or a μ-opioid receptor, to a sample to which it is administered.

For example, in one system, the D9-THC activity of cannabinoid receptor 1 (CB1) has a consistent EC50 of about 1 micromolar and 40-50% compared to a known, synthetic full agonist (CP-55,940). the response magnitude. The lower response of CB1 to THC relative to full agonists is why THC is known as a "partial agonist" of the CB1 receptor.

In some embodiments, the purposely designed formulations disclosed herein are developed by establishing the EC50 of THC multiple times in CB1 and determining the EC50 of THC in the background of constant concentrations of other cannabinoids and terpenes. This is an example of a method used to determine how a particular cannabis component synergizes, adds to, or competes with the THC response itself.

Using these purposefully designed combinations (rather than naturally occurring ones) provides users with quantitative control over the underlying pharmacology and biochemistry responsible for the observed physical and psychological effects. Thus, the compositions disclosed herein provide unprecedented control over the effects of cannabinoids and/or terpenes on the user.

In one embodiment, the composition reduces the EC50 of either or both of the first purified cannabinoid and/or the second purified cannabinoid at a particular receptor.

In one embodiment, the composition provides a first purified cannabinoid and/or a second purified cannabinoid for a specific receptor such as CB1, CB2, GPR55, 5HT-1A, 5HT-2A, TRPV1, and/or μ-opioid receptors An increase in the EC50 of either or both of the purified cannabinoids.

In one example, the compositions disclosed herein alter the EC50 of THC at the CB1 receptor. In one embodiment, by using the synergistic compositions disclosed herein, the EC50 of THC is modulated to provide novel beneficial properties.

In one example, the THC activity of the CB1 receptor has a consistent EC50 of about 1 micromolar and a 40-50% response amplitude compared to known, synthetic full agonists (eg, CP-55,940).

In one example, the synergistic benefits of the compositions disclosed herein can be demonstrated by measuring the EC50 of THC alone at CB1 and then comparing it to the EC50 of THC at CB1 in the presence of other cannabinoids and terpenes.

In one example, the disclosed compositions provide a synergistic effect relative to a reference cannabinoid administered alone. In one example, the disclosed composition augments the effect of a reference cannabinoid. In one example, the disclosed composition competes with the reference cannabinoid for the CB1 receptor.

In one example, the disclosed composition provides a synergistic effect relative to THC alone.

In one example, the disclosed composition increases the effect of THC alone.

Accordingly, the compositions disclosed herein provide a method of increasing the response of THC at the CB1 receptor (relative to THC alone), comprising administering THC with a terpene.

In one embodiment, the purified terpenes are selected from the group consisting of limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha- Bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinene, menthone, camphene, or geraniol .

Disclosed herein is to increase the potency of a first purified cannabinoid together with a first purified terpene on receptors such as CB1, CB2GPR55, 5HT-1A, 5HT-2A, TRPV1, serotonin receptors, mu-opioid receptors, etc. Methods. In one embodiment, increasing the potency at the receptor includes a second purified cannabinoid. In one embodiment, increasing the potency at the receptor includes a second purified terpene.

In one embodiment, the compositions disclosed herein provide a method of increasing the response of THC at the CB1 receptor (relative to THC alone) comprising administering THC with a terpene. In one example, the method of increasing the efficacy of THC includes administering THC with alpha-humulene. In one example, the method of increasing the efficacy of THC includes administering THC with linalool. In one example, the method of increasing the efficacy of THC includes administering THC with nerolidol. In one example, the method of increasing the efficacy of THC includes administering THC with limonene. In one example, the method of increasing the efficacy of THC includes administering THC with alpha-terpineol. In one example, the method of increasing the efficacy of THC includes administering THC with beta-pinene. In one example, the method of increasing the efficacy of THC includes administering THC with paracymene. In one example, the method of increasing the efficacy of THC includes administering THC with eucalyptol.

In one embodiment, the compositions disclosed herein provide a method of increasing the response of THC at CB1 receptors (relative to THC alone) comprising administering THC with a second cannabinoid. In one example, the method of increasing the efficacy of THC includes administering THC with CBC. In one example, the method of increasing the efficacy of THC includes administering THC with CBG. In one example, the method of increasing the efficacy of THC includes administering THC with THCV. In one example, the method of increasing the efficacy of THC includes administering THC with CBD.

In one example, the disclosed composition competes with TH1 at the CB1 receptor.

In one example, by formulation comprising purified THC and selected from the group consisting of limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, Alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinolene, menthone, camphene or incense A composition of purified terpenes of leaf alcohol to lower the EC50 of THC in CB1 (relative to THC alone).

In one example, the EC50 of THC at CB1 (relative to THC alone) was increased by formulating a composition comprising purified THC and beta-caryophyllene.

In one embodiment of the compositions disclosed herein, the phrase "comprising purified THC and purified terpenes" means that the composition comprises a combined terpene content of about 0.5% to about 10%.

An exemplary non-limiting terpene is linalool. One embodiment of the present disclosure comprises 0.5-1% purified linalool. One embodiment of the present disclosure comprises 1-2% purified linalool. One embodiment of the present disclosure comprises 2-5% purified linalool. One embodiment of the present disclosure comprises 5-10% purified linalool.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified limonene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified nerolidol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β-myrcene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified linalool.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-caryophyllene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β-caryophyllene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-pinene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β-pinene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-bisabolol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified delta-3-carene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified borneol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified eucalyptol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-terpineol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified p-cymene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-humulene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified terpinolene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified menthone.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified camphene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified geraniol.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while decreasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while decreasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while decreasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB1 while decreasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while decreasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while decreasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while decreasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at CB2 while decreasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while decreasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while decreasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while decreasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at GPR55 while decreasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A, while decreasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A, while decreasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A, while decreasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-1A, while decreasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while decreasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while decreasing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A while decreasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the EC50 of a first cannabinoid at 5HT-2A, while decreasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at GPR55, while reducing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-1A, while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-1A, while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed compositions decrease the EC50 of a first cannabinoid at 5HT-1A, while increasing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-1A, while reducing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-1A, while reducing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-1A, while reducing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-1A, while reducing the EC50 of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition decreases the EC50 of a first cannabinoid at 5HT-2A, while increasing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-2A, while reducing the EC50 of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-2A, while reducing the EC50 of a second cannabinoid at CB2.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-2A, while reducing the EC50 of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the EC50 of a first cannabinoid at 5HT-2A, while reducing the EC50 of a second cannabinoid at 5HT-1A.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified limonene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified nerolidol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β-myrcene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified linalool.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-caryophyllene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β-caryophyllene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-pinene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β-pinene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-bisabolol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified delta-3-carene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified borneol.

In one example, the magnitude of the response of THC at CB1 was reduced by formulating a composition comprising purified THC and purified eucalyptol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-terpineol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified paracymene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-humulene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified terpinolene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified camphene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified geraniol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified menthone.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified limonene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified nerolidol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified β-myrcene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified linalool.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-caryophyllene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified β-caryophyllene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-pinene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified β-pinene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-bisabolol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified delta-3-carene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified borneol.

In one example, the magnitude of the response of THC at CB1 was increased by formulating a composition comprising purified THC and purified eucalyptol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-terpineol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified paracymene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-humulene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified camphene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified terpinolene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified geraniol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified menthone.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB1 while increasing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB1 while increasing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB1 while increasing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB1 while increasing the magnitude of the response of the second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid to 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB2 while increasing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB2 while increasing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at CB2 while increasing the magnitude of the response of the second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB2, while decreasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB2, while decreasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB2, while decreasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at CB2 while decreasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at GPR55 while increasing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at GPR55 while increasing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at GPR55 while increasing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at GPR55 while increasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at GPR55, while decreasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at GPR55, while decreasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at GPR55, while decreasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at GPR55, while decreasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-1A, while increasing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-1A while increasing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-1A, while increasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-1A, while increasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-1A, while decreasing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-1A, while decreasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-1A, while decreasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-1A, while decreasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-2A while increasing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-2A while increasing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-2A while increasing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of the first cannabinoid at 5HT-2A while increasing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-2A, while decreasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-2A, while decreasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-2A, while decreasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition increases the magnitude of the response of a first cannabinoid at 5HT-2A, while decreasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition decreases the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition decreases the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition decreases the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB1 while reducing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB1 while reducing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB1 while reducing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB1 while reducing the magnitude of the response of the second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at CB2, while increasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at CB2, while increasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB2 while reducing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB2 while reducing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB2 while reducing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at CB2 while reducing the magnitude of the response of the second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at GPR55, while increasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at GPR55 while increasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition decreases the magnitude of the response of a first cannabinoid at GPR55, while increasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at GPR55 while increasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at GPR55 while reducing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at GPR55 while reducing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at GPR55 while reducing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at GPR55 while reducing the magnitude of the response of the second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-1A, while increasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-1A, while increasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-1A, while increasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-1A, while increasing the magnitude of the response of a second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-1A while reducing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-1A while reducing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-1A, while reducing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-1A, while reducing the magnitude of the response of the second cannabinoid at 5HT-2A.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-2A, while increasing the magnitude of the response of a second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-2A, while increasing the magnitude of the response of a second cannabinoid at CB2.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-2A, while increasing the magnitude of the response of a second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of a first cannabinoid at 5HT-2A, while increasing the magnitude of the response of a second cannabinoid at 5HT-1A.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-2A while reducing the magnitude of the response of the second cannabinoid at CB1.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-2A while reducing the magnitude of the response of the second cannabinoid at CB2.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-2A while reducing the magnitude of the response of the second cannabinoid at GPR55.

In one example, the disclosed composition reduces the magnitude of the response of the first cannabinoid at 5HT-2A, while reducing the magnitude of the response of the second cannabinoid at 5HT-1A.

In one example of the above embodiment, in a composition comprising THC and alpha-humulene, the EC50 of THC at CB1 is decreased.

In one embodiment, the EC50 of THC at CB1 is reduced to between about 0.1 micromolar to about 0.5 micromolar.

In an example of the above embodiment, in a composition comprising THC and linalool, the EC50 of THC at CB1 is reduced.

In one embodiment, the EC50 of THC at CB1 is reduced to between about 0.05 micromolar to about 0.2 micromolar.

The above examples of cellular effects can be further correlated with the results of clinical studies, such as those exemplified in this application.

As used herein, the term "cannabinoid" refers to a compound that belongs to a class of secondary compounds commonly found in plants of the Cannabis genus. In one embodiment, cannabinoids are present in plants, such as Cannabis, and are sometimes referred to as phytocannabinoids. In one embodiment, cannabinoids are found in mammals and are sometimes referred to as endocannabinoids. In one embodiment, cannabinoids are prepared in a laboratory setting, sometimes referred to as synthetic cannabinoids. In one embodiment, cannabinoids act on cellular receptors, such as G-coupled protein receptors (eg, serotonin receptors, cannabinoid receptors, TRPV1, opioid receptors, etc.), thereby causing damage to the brain or body reaction. In one embodiment, cannabinoids affect the activity of other compounds at one or more receptors by acting as agonists, partial agonists, inverse agonists, antagonists, and the like.

In many cases, cannabinoids can be identified because their chemical name will contain the text string "*cannabi*" in the name.

In the context of this application, when referring to a specific cannabinoid, each of the acid and/or decarboxylated forms is considered to be a single molecule and a mixture.

Examples of cannabinoids include, but are not limited to, cannabinoid (CBGA), cannabinol monomethyl ether (CBGAM), cannabinol (CBG), cannabinol monomethyl ether (CBGM), subcannabinol ( CBGVA), Cannabidiol (CBGV), Cannabidiolic Acid (CBCA), Cannabidiolic Acid (CBCA), Cannabidiolic Acid (CBCVA), Cannabidiolic Acid (CBDA) , Cannabidiol (CBD), Cannabidiol Monomethyl Ether (CBDM), Cannabidiol-C ₄ (CBD-C ₄ ), Cannabidiol Acid (CBDVA), Cannabidiol (CBDV), Cannabidiol Phenol (CBD-C ₁ ), Tetrahydrocannabinol A (THCA-A), Tetrahydrocannabinol B (THCA-B), Tetrahydrocannabinol (THCA), Tetrahydrocannabinol (THC), Tetrahydrocannabinol (THCA) Hydrocannabinol C ₄ (THCA-C ₄ ), Tetrahydrocannabinol C ₄ (THC-C ₄ ), Tetrahydrocannabinol (THCVA), Tetrahydrocannabinol (THCV), THC (THCA-C ₁ ), tetrahydrocannabinol (THC-C ₁ ), Δ ⁷ -cis-isotetrahydrocannabinol, Δ ⁸ -tetrahydrocannabinolic acid (Δ ⁸ -THCA), hypocannabidiolic acid (CBNDVA), Cannabidiol (CBNDV), Δ8-Tetrahydrocannabinol ( ^Δ8 -THC), ^Δ9 -Tetrahydrocannabinol ( ^Δ9 -THC), ^Cannabidiol (CBLA), Cannabidiol Cannabidiol (CBL), Cannabidiol (CBLV), Cannabidiol A (CBEA-A), Cannabidiol B (CBEA-B), Cannabidiol (CBE), Cannabidiol (CBEV), Cannabidiol (CBEVA), Cannabidiol (CBEA), Cannabidiol (CBLV), Cannabidiol (CBLVA), Cannabidiol (CBNA), Cannabidiol ( CBN), Cannabidiol (CBNVA), Cannabidiol Monomethyl Ether (CBNM), Cannabidiol-C ₄ (CBN-C ₄ ), Cannabidiol (CBV), Cannabidiol-C ₂ (CBN-C ₂ ) , Cannabidiol (CBN-C ₁ ), Cannabidiol (CBND), Cannabidiol (CBNDA), Cannabidiol (CBDV), Cannabidiol (CBT), 10-Ethoxy-9 -Hydroxy- ^Δ6a -tetrahydrocannabinol, 8,9-dihydroxy-Δ6a ^(10a) -tetrahydrocannabinol (8,9-Di-OH-CBT- _C5 ), dihydroxycannabinol (CBTV ), ethoxy-dihydroxycannabinol (CBTVE), dihydrocannabidiol (DCBF), cannabidiol (CBF), cannabidiol (CBCN), cannabidiol (CBT) , 10-oxy-Δ6a ^(10a) -tetrahydrocannabinol (OTHC), ^Δ9 -cis-tetrahydrocannabinol ( cis-THC), Cannabiripsol (CBR), 3,4,5,6-Tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methanol-2H- 1-benzoxazoloctane-5-methanol (OH-iso-HHCV), trihydroxy-delta-9-tetrahydrocannabinol (tri-OH-THC), buckwheat, epigallocatechin gallate, ten Dioxane-2E,4E,8Z,10Z-tetraenoic acid isobutylamide, and dodecane-2E,4E-dienoic acid isobutylamide.

In one embodiment, the purified cannabinoid is selected from the group consisting of THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV or CBLVA.

As used herein, the term "THC" refers to tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising THC are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "THCA" refers to tetrahydrocannabinolic acid and has the following structural formula:

THCA is decarboxylated with heat, light, etc. to form THC, D8-THC, D9-THC and other potential cannabinoids. In the context of the present disclosure, THCA-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "THCV" refers to tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising THCV are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "THCVA" refers to tetrahydrocannabinolic acid and has the following structural formula:

Decarboxylation of THCVA with heat, light etc. forms THCV, D8-THCV, D9-THCV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising THCVA are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "D8-THC" refers to delta-8-tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising D8-THC are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "D8-THCV" refers to delta-8-tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising D8-THCV are formulated with other compounds to provide previously unobtainable potency, control, identity, purity, etc.

As used herein, the term "D9-THC" refers to delta-9-tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising D9-THC are formulated with other compounds to provide potency, control, identity, purity, etc. that were not previously available.

As used herein, the term "D9-THCV" refers to delta-9-tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising D9-THCV are formulated with other compounds to provide previously unobtainable potency, control, identity, purity, etc.

As used herein, the term "CBD" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, CBD-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBDA" refers to cannabidiolic acid and has the following structural formula:

CBDA is decarboxylated with heat, light, etc. to form CBD and other possible cannabinoid derivatives. In the context of the present disclosure, CBDA-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBDV" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBDV are formulated with other compounds to provide previously unobtainable potency, control, identity, purity, etc.

As used herein, the term "CBDVA" refers to cannabidiolic acid and has the following structural formula:

CBDVA is decarboxylated with heat, light, etc. to form CBDV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBDVA are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBC" refers to cannachromene and has the following structural formula:

In the context of the present disclosure, compositions comprising CBC are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBCA" refers to cannabinoid and has the following structural formula:

CBCA is decarboxylated with heat, light, etc. to form CBC and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBCA are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBCV" refers to hypocannabinoid and has the following structural formula:

In the context of the present disclosure, compositions comprising CBCV are formulated with other compounds to provide previously unobtainable potency, control, identity, purity, etc.

As used herein, the term "CBCVA" refers to cannabidinic acid and has the following structural formula:

CBCVA is decarboxylated with heat, light, etc. to form CBCV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBCVA are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBG" refers to cannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBG are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBGA" refers to cannabinol acid and has the following structural formula:

CBGA is decarboxylated with heat, light, etc. to form CBG and other possible cannabinoid derivatives. In the context of the present disclosure, CBGA-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBGV" refers to subcannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBGV are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBGVA" refers to hypocannabinol acid and has the following structural formula:

CBGVA is decarboxylated with heat, light, etc. to form CBGV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBGVA are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBN" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, CBN-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBNA" refers to cannabidiolic acid and has the following structural formula:

CBNA is decarboxylated with heat, light, etc. to form CBN and other possible cannabinoid derivatives. In the context of the present disclosure, CBNA-containing compositions are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBNV" or "CBV" refers to subcannabinol and has the following structural formula:

In the context of the present disclosure, CBNV-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBNVA" refers to hypocannabinolic acid and has the following structural formula:

CBNVA is decarboxylated with heat, light, etc. to form CBNV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBNVA are formulated with other compounds to provide previously unobtainable potency, control, identity, purity, etc.

As used herein, the term "CBND" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, CBND-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBNDA" refers to cannabidiolic acid and has the following structural formula:

CBNDA is decarboxylated with heat, light, etc. to form CBND and other possible cannabinoid derivatives. In the context of the present disclosure, CBNDA-containing compositions are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBNDV" refers to sub-cannabidiol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBNDV are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBNDVA" refers to cannabidiolic acid and has the following structural formula:

CBNDVA is decarboxylated with heat, light, etc. to form CBNDV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBNDVA are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBL" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, CBL-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBLA" refers to cannabidiol and has the following structural formula:

CBLA is decarboxylated with heat, light, etc. to form CBL and other possible cannabinoid derivatives. In the context of the present disclosure, CBLA-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBLV" refers to subcannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBLV are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBLVA" refers to hypocannabinolic acid and has the following structural formula:

CBLVA is decarboxylated with heat, light, etc. to form CBLV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBLVA are formulated with other compounds to provide previously unobtainable potency, control, consistency, purity, etc.

As used herein, the term "CBE" refers to Cannabis Elson and has the following structural formula:

In the context of the present disclosure, CBE-containing compositions are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBEA" refers to Cannabis Elsonic Acid and has the following structural formula:

CBEA is decarboxylated with heat, light, etc. to form CBE and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBEA are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBEV" refers to Cannabinoid Elson and has the following structural formula:

In the context of the present disclosure, compositions comprising CBEV are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "CBEVA" refers to cannabinoid elsonic acid and has the following structural formula:

CBEVA is decarboxylated with heat, light, etc. to form CBEV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBEVA are formulated with other compounds to provide potency, control, consistency, purity, etc. that were not previously available.

As used herein, the term "terpene" refers to a compound built on an isoprenoid structure or produced by combining isoprene units, a 5-carbon structure. Terpenes are also involved in the production of odors in plants where terpenes are part of a class of secondary compounds. In one embodiment, the terpenes are hydrocarbons.

In the context of this disclosure, the term "terpene" does not necessarily require 5 carbons or multiples of 5 carbons. It will be appreciated that reaction with isoprene units does not always yield terpenes containing all carbon atoms.

In the context of this disclosure, the term "terpenes" includes hemiterpenes, monoterpene alcohols, terpene esters, diterpenes, monoterpenes, polyterpenes, tetraterpenes, terpenoid oxides, disesquiterpenes , sesquiterpenes, norisoprene, or their derivatives. And isomeric, enantiomeric or optically active derivatives.

Derivatives of terpenes include terpenoids, hemiterpenoids, monoterpenoids, sesquiterpenoids, disesquiterpenoids, trisesquiterpenoids, tetraterpenoids, triterpenoids , tetraterpenoids, polyterpenoids, isoprenoids and steroids.

In the context of this disclosure, the term terpene includes alpha-(alpha), beta-(beta), gamma-(gamma), oxo-, isomers, or any combination thereof.

Examples of terpenes in the context of this disclosure include: 7,8-dihydro-alpha-ionone, 7,8-dihydro-beta-ionone, acetyl anisole, acetic acid, acetyl cedarene, anise Brain, Anisole, Benzaldehyde, Bergamotene (alpha-cis-bergamotene) (alpha-trans-bergamotene), bisabolol (beta-bisabolol), alpha-bisabolol, borneol, borneol acetate Esters, Butanoic/Butyric Acid, juniperene (α-juniperene) (γ-juniperene), cafestol, caffeic acid, camphene, camphor, capsaicin, carene (δ-3- Carene), Humulene, Carvacrol, D-Carvone, L-Carvone, Alpha-Caryophyllene, Beta-Caryophyllene, Caryophyllene Oxide, Cedarene (α-Cedrugene) (β-Cedricene) alkene), cedarene epoxide (α-cedrene epoxide), cedaryl alcohol, coniferene, chlorogenic acid, cinnamaldehyde, α-pentylcinnamaldehyde, α-hexylcinnamaldehyde, cinnamic acid, cinnamyl alcohol, Citronellal, Citronellol, Cryptopinone, Curcumene (α-Curcumene) (γ-Curcumene), Decanal, Dehydroemetic Raufol, Diallyl Disulfide, Dihydrokiwi Ester, dimethyl disulfide, eicosane (eicosane/icosane), elemene (beta-elemene), artemole, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol/ 1,8-Cineole, Eucalyptol (α-Cineole) (β-Cineole) (γ-Cineole), Eugenol, Euphorbiol, Farnesene, Acacia Alcohol, Fenugreek (β-Fenol), Fenugreek, Geraniol, Geranyl Acetate, Macrogeranene, Macrogeranene B, Guaiac-1(10),11-diene, Guaiac Lignol, guaiacene (α-guaiacene), guarene (α-guarene), 7-methoxycoumarin, hexanal (Hexanaldehyde), hexanoic acid, humulene (α - humulene) (beta-humulene), ionol (3-oxo-alpha-ionol) (beta-ionol), ionone (alpha-ionone) (beta-ionone), dentate Dienol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isobornol, isomyrcenol, isopulegol, isovaleric acid, isoprene, kahweol, lavender alcohol, Limonene, gamma-linolenic acid, linalool, longifolene, alpha-longifolinene, lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, thiol/thiol , β-mercaptoethanol, thioglycolic acid, allyl mercaptan, benzyl mercaptan, butyl mercaptan, ethyl mercaptan, methyl mercaptan, furfuryl mercaptan, ethanedithiol, propyl mercaptan, Thienomethylthiol, Methyl Salicylate, Methylbutenol, Methyl 2-Methylvalerate, Methyl Thiobutyrate, Myrcene (β-Myrcene), γ-Ylangolene, Nepetalactone, nerol, nerol, neryl acetate, nonanal, nonanoic acid, basilene, octanal, caprylic acid, p-cymene, amyl butyrate, phellandrene, phenylacetaldehyde , Phenylethanethiol, Phenylacetic acid, Phytol, Pinene, Beta-pinene, Propanethiol, Phyllophyllin, Menthone, Quercetin, Retinol, Rutin, Sininene, Sininene Hydrate , cis-Sinkyrene hydrate, trans-Sinkyrene hydrate, crocetin, alpha-epidylene, alpha-sinneral, beta-sinneral, beta-sitosterol, squalene, taxane Diene, terpinene hydrate, terpineol, terpinen-4-ol, alpha-terpinene, gamma-terpinene, terpinene, thiophenol, thujone, thymol, alpha-tocopherol Phenol, coumaric undecanone, undecanal, valeraldehyde, o-tert-butylcyclohexyl acetate, alpha-irane, umbelliferone or vanillin.

As used herein, the term "7,8-dihydro-alpha-ionone" refers to a compound having the following structural formula:

7,8-Dihydro-alpha-ionone is often characterized as having a woody, floral odor.

As used herein, the term "7,8-dihydro-beta-ionone" refers to a compound having the following structural formula:

7,8-Dihydro-beta-ionone is often characterized as having a woody aroma.

As used herein, the term "acetyl anisole" refers to a compound having the following structural formula:

Acetylanisole typically has a sweet, aniseed, vanilla aroma with powdery, balsamic and benzaldehyde nuances. Acetyl anisole is also used as a flavoring agent.

As used herein, the term "acetic acid" refers to a compound having the following structural formula:

Acetic acid is often characterized as one of the main components of vinegar.

As used herein, the term "acetyl cedarene" refers to a compound having the following structural formula:

Acetyl cedarene typically has a warm, woody, amber musk aroma. Acetyl cedarene is also a spice.

As used herein, the term "anethole" refers to an aromatic compound having the following structural formula:

Anethole usually has a sweet, aniseed, licorice flavor. Anethole is used in various flavors and fragrances.

As used herein, the term "anisole" refers to a compound having the following structural formula:

Anisole is often characterized by smelling like fennel seeds.

As used herein, the term "benzaldehyde" refers to a compound having the following structural formula:

Benzaldehyde often has an almond-like odor.

As used herein, the term "bergamotene" refers to a compound comprising one or both of a-cis-bergamotene and/or a-trans-bergamotene in pure and/or mixture in any ratio.

Alpha-cis-bergamotene refers to a compound having the following structural formula:

Alpha-cis-bergamotene is generally characterized by a strong black pepper odor. Alpha-cis-bergamotene is a fragrance component of many species of the orchid family.

Alpha-trans-bergamotene refers to the following structural formula:

Alpha-trans-bergamotene is generally characterized by a medium-intensity, warm tea-like odor. Alpha-trans-bergamotene is used in the chemical communication system of certain species of aphids.

As used herein, the term "bisabolol" refers to a compound comprising one or both of alpha-bisabolol and/or beta-bisabolol in pure and/or mixture in any ratio.

Alpha-Bisabolol refers to a compound having the following structural formula:

Alpha-Bisabolol is generally characterized as the active ingredient of chamomile.

Beta-bisabolol refers to a compound having the following structural formula:

Beta-Bisabolol is generally characterized by a citrus, floral, lemon, sweet, herbal aroma.

As used herein, the term "bornol" refers to a compound having the following structural formula:

Borneol is often characterized by a menthol aroma, similar to camphor. Borneol can also be converted into camphor.

As used herein, the term "bornyl acetate" refers to a compound having the following structural formula:

Bornyl acetate is generally characterized by a pine, camphor, herbal and balsamic odor.

As used herein, "butyric/butyric acid" refers to a compound having the following structural formula:

Butyric acid is often characterized as having an unpleasant pungent odor commonly found in sweat, flatulence, and rancid butter.

As used herein, the term "juniperene" refers to a compound comprising one or both of alpha-juniperene and/or gamma-juniperene in pure and/or mixtures in any ratio.

Alpha-juniperene refers to a compound having the following structural formula:

Alpha-juniperpenes are generally characterized by a spicy, smoky, woody, guaiac-like odor.

Gamma-juniperene refers to a compound having one of the following structural formulas:

or Gamma-juniperene is generally characterized by a herbal, herbal, woody aroma. Gamma-juniper terpenes have some antibacterial properties. Many species of termites and some beetles use gamma-juniperene in their chemical communication systems.

As used herein, the term "caffeicol" refers to a compound having the following structural formula:

Cafetol is generally characterized as a major constituent of coffee.

As used herein, the term "caffeic acid" refers to a compound having the following structural formula:

Caffeic acid is often characterized as a key intermediate in lignin synthesis.

As used herein, the term "camphene" refers to a compound having the following structural formula:

Camphene is generally characterized by a spicy, herbal, fir-leaf odor. Camphene is used in perfumes and food additives. Camphene is a minor constituent of many essential oils such as turpentine, cypress, camphor, citronella, neroli, ginger, and valerian.

As used herein, the term "camphor" refers to a compound having one of the following structural formulas:

or In the context of the present disclosure, the term "camphor" includes enantiomers, either in single form or in mixtures in any ratio. Camphor has a very characteristic smell for which the tree is named. Camphor is used as a flavor and fragrance for chewing gum, hard candy, etc.

As used herein, the term "capsaicin" refers to a compound having the following structural formula:

Capsaicin is usually tasteless. Capsaicin is generally characterized as an irritant to mammals, which is known to induce sensation upon inhalation, consumption or application to the skin.

As used herein, the term "carene" or "delta-3-carene" refers to a compound having the following structural formula:

Delta-3-carene, sometimes referred to as "carene," is often described as having a sweet and pungent odor.

As used herein, the term "humulene" refers to any of a series of related compounds having the formula C40Hx.

In the context of the present disclosure, the term "humulene" refers to any isomeric form of humulene in pure and/or mixture in any ratio. Humulene is generally characterized as an important compound in the process of photosynthesis.

As used herein, the term "carvacrol" refers to a compound having the following structural formula:

Carvacrol is often characterized by a pungent odor of oregano. Carvacrol is often used as a spice and flavor, and its flavor has been described as spicy, herbal, phenolic, medicinal, and woody.

As used herein, the term "D-carvone" refers to the S-(+) enantiomer of carvone, having the following structural formula:

D-carvone usually has a spicy, toasty and coriander smell. D-carvone is found in citrus peel oil and gingergrass oil. D-carvone is the main component of coriander seed oil.

As used herein, the term "L-carvone" refers to the R-(-) enantiomer of carvone having the following structural formula:

L-carvone is generally characterized by a sweet, minty, herbal, spearmint aroma. L-carvone is found in spearmint and linden oil.

As used herein, the term "beta-caryophyllene" refers to a compound having the following structural formula:

Beta-caryophyllene is often characterized as the flavor component of black pepper. Beta-Caryophyllene is commonly referred to as Caryophyllene.

As used herein, the term "caryophyllene oxide" refers to a compound having the following structural formula:

Caryophyllene oxides are often characterized by a lemon balm odor.

As used herein, the term "cedrene" refers to either or both of alpha-cedrene and/or beta-cedene, either in pure form or as a mixture in any proportion.

Alpha-cedrene refers to a compound having the following structural formula:

Alpha-cedarene is generally characterized by a medium-strength, woody, sweet, fresh cedar aroma. Alpha-cedarene is used in baked goods, sherbet and sorbets. Alpha-cedrene is the main component of cedarene essential oil.

Beta-cedrene refers to a compound having the following structural formula:

β-Cedarene is generally characterized by a woody aroma of cedar. Beta-cedarene is the main component of cedarwood essential oil.

As used herein, the term "cedrene epoxide" or "alpha-cedrene epoxide" refers to a compound having the following structural formula:

Alpha-cedarene epoxides are generally characterized by woody, amber, tobacco, sandalwood and fresh patchouli odors. Alpha-cedrene epoxides are commonly used as fragrances and fragrances in cosmetics.

As used herein, the term "cedar alcohol" refers to a compound having the following structural formula:

Cedarol is generally characterized as having a very faint aroma, sweetness, cedarwood and woodiness. Cedar alcohol is the main component of cedar wood oil.

As used herein, the term "coniferene A" refers to a compound having the following structural formula:

Coniferene A is generally characterized by a faint waxy odor.

As used herein, the term "chlorogenic acid" refers to a compound having the following structural formula:

Chlorogenic acid can usually be found in peaches, plums and green coffee bean extracts.

As used herein, the term "cinnamaldehyde" refers to a compound having the following structural formula:

Cinnamaldehyde is generally characterized by a spicy, sweet cinnamon odor and imparts a cinnamon flavor. Cinnamaldehyde occurs naturally in the bark of the cinnamon tree and other species of the genus Cinnamomum.

As used herein, the term "alpha-hexyl-cinnamaldehyde" refers to a compound having the following structural formula:

Alpha-hexyl-cinnamaldehyde is generally characterized by sweet, floral, green, jasmine, citrus and fruity aromas, with powdery, tropical or spicy flavors.

As used herein, the term "alpha-pentyl-cinnamaldehyde" refers to a compound having the following structural formula:

Alpha-pentyl-cinnamaldehyde is generally characterized by sweet, floral, fruity, herbal, jasmine and tropical aromas.

As used herein, the term "cinnamic acid" refers to a compound having the following structural formula:

Cinnamic acid is generally characterized by a balsamic, sweet, benzoin, honey-like odor. Cinnamic acid comes from cinnamon oil or from balsams such as benzoin.

As used herein, the term "cinnamyl alcohol" refers to a compound having the following structural formula:

Cinnamyl alcohol is often characterized by cinnamon spice, cyanine and fermented odors, and powdered balsamic nuances. As a flavor component, cinnamon alcohol has green, floral, spicy and honey flavors with fermented yeast nuances.

As used herein, the term "citronellal" refers to a compound having the following structural formula:

Citronellal is often characterized by up to 80% of the leaf oil from kaffir lime leaves and serves as a characteristic aroma.

As used herein, the term "citronellol" refers to either or both of the (+) and (-) enantiomers, either in pure form or as a mixture in any ratio.

The (+) enantiomer has the following structural formula:

The (-) form has the following structural formula:

Citronellol is generally floral, rosy, sweet, citrus with a green, fatty, terpene subtle odor.

As used herein, the term "cryptopone" refers to a compound having the following structural formula:

Cryptopinone usually has a woody mint herbal odor.

As used herein, the term "curcumene" refers to either or both of alpha-curcumene and/or gamma-curcumene, either in pure form or as a mixture in any ratio.

Alpha-curcumene has the following structural formula:

Alpha-curcumene is often characterized by an odor similar to turmeric. Alpha-curcumene is mainly found in the ginger genus Zingiber.

Gamma-curcumene has the following structural formula:

Gamma-curcumene is often characterized by an earthy odor. Gamma-curcumene is mainly found in the Libocedrus bidwillii tree in New Zealand.

As used herein, the term "decanal" refers to a compound having the following structural formula:

Decanal is often characterized by a citrus odor. Decanal is used as a spice and flavoring agent.

As used herein, the term "dehydroemeticolol" refers to a compound having the following structural formula:

DHEM is generally characterized by fruity and floral aromas.

As used herein, the term "diallyl disulfide" refers to a compound having the following structural formula:

Diallyl disulfides are often characterized by a strong, off-flavored onion and garlic-like odor.

As used herein, the term "dihydrokiwifruit lactone" refers to a compound having the following structural formula:

Dihydrokiwifruit lactones are generally characterized by a fruity, musky, coumarin tea-like, peach aroma.

As used herein, the term "dimethyl disulfide" refers to a compound having the following structural formula:

Dimethyl disulfide is generally characterized by a sulfur-containing, putrid odor.

As used herein, the term "eicosane" or "icosane" refers to a compound of formula _C20H42 and having _366,619 constitutional isomers with the following skeletal structure:

Eicosanoid is usually characterized by a waxy odor. Eicosan is used in flavor concentrates.

As used herein, the term "beta-elemene" refers to a compound having the following structural formula:

Beta-elemene is generally characterized by a sweet aroma.

As used herein, the term "artemisinin" refers to a compound having the following structural formula:

Artemisinol is an isomer of anethole. Artemisia is usually characterized by an fennel seed odor and is present in tarragon oil, turpentine and other essential oils.

As used herein, the term "ethyl acetate" refers to a compound having the following structural formula:

Ethyl acetate is generally characterized by an acidic, fruity, cloudy, cheesy, fermented odor.

As used herein, the term "ethyl cinnamate" refers to a compound having the following structural formula:

Ethyl cinnamate is generally characterized by sweet, balsamic, spicy, fruity, berry, and plum flavors.

As used herein, the term "ethyl maltol" refers to a compound having the following structural formula:

Ethyl maltol is generally characterized by a sweet taste similar to caramel and cooked fruit.

As used herein, the term "cineole" refers to a terpene having the following structural formula:

Eucalyptol is usually characterized by a minty flavor. Eucalyptol is also known as 1,8-cineole, 1,8-cineole, cineole, 1,8-epoxy-p-menthane, 1,8-oxy-p-menthane, eucalyptus Olein, eucalyptol, 1,3,3-trimethyl-2-oxabicyclo[2,2,2]octane, cineole and eucalyptol.

As used herein, the term "eucalyptol" refers to alpha-eucalyptol, beta-eucalyptol, or gamma-eucalyptol, either in pure form or as a mixture in any ratio.

Alpha-eucalyptol has the following structural formula:

Alpha-eucalyptol is generally characterized by a sweet, woody odor.

Beta-eucalyptol has the following structural formula:

Beta-eucalyptol is generally characterized by a sweet, green, woody, grapefruit-like aroma.

Gamma-eucalyptol has the following structural formula:

Gamma-eucalyptol is generally characterized by a waxy, sweet, woody and floral aroma.

As used herein, the term "eugenol" refers to a compound having the following structural formula:

Eugenol is often characterized by causing the aromatic odor of cloves. Eugenol is present in insect attractants and UV absorbers.

As used herein, the term "euphorbienol" refers to a compound having the following structural formula:

Euphorbia is generally characterized as the major constituent in the sap of Euphorbia tirucalli.

As used herein, the term "farnesene" refers to six closely related compounds. (E,E)-α-Farnesene is one of these six molecules and has the following structural formula:

In the context of this disclosure, the term "farnesene" refers to any one of six closely related compounds, alone or in combination with any other of these six closely related compounds. Farnesene is generally characterized by a magnolia flower aroma and has a citrus aroma with a green, woody, vegetal smell with a hint of lavender.

As used herein, the term "farnesol" refers to a compound having the following structural formula:

Farnesol is generally characterized as having a mild, fresh, sweet, floral, linden odor. Farnesol is used in cosmetics, flavors and fragrances.

As used herein, the term "fenol" or "beta-fenol" refers to a compound having the following structural formula:

Beta-Fenol is generally characterized by a camphor, pine, woody, dry, sweet, lemon aroma. Beta-Fenol is used as a fragrance and essence.

As used herein, the term "fenchone" refers to a compound having the following structural formula:

Fenugreek is generally characterized by camphor, thuja, cedar leaf, herbal, earthy, woody aromas.

As used herein, the term "geraniol" refers to a compound having the following structural formula:

Geraniol is often characterized by a sweet rose-like aroma.

As used herein, the term "geranyl acetate" refers to a compound having the following structural formula:

Geranyl acetate is generally characterized by a floral and fruity aroma. Geranyl acetate is found in various natural oils from plants such as citronella, lemongrass, sassafras, rose and various others.

As used herein, the term "gernesol" refers to a compound having the following structural formula:

Geranitol is usually characterized as a clear, colorless liquid.

As used herein, the term "macrogeranene" refers to a class of hydrocarbons. In the context of the present disclosure, the term "geranene macrophylla" refers to any of the five isomers, either in pure form or in any combination of the five isomers.

Geraniene A refers to the following structural formula:

Geraniene B refers to the following structural formula:

Geraniene C refers to the following structural formula:

Geraniene D refers to the following structural formula:

Geranene E refers to the following structural formula:

As used herein, the term "guaiac-1(10),11-diene" refers to a compound having the following structural formula:

Guaiac-1(10),11-diene is generally characterized by a sweet, woody aroma. Guaiac-1(10),11-diene is used as a flavor in a variety of products, from food additives, tobacco flavorings and general cosmetics to flavoring rooms.

As used herein, the term "guaiacol" refers to a compound having the following structural formula:

Guaiol is generally characterized by a smoky, spicy, woody, medicinal odor. Guaiacol has a sweet, powdery, musty, vanilla, floral, and almond flavor.

As used herein, the term "alpha-guaiacene" refers to a compound having the following structural formula:

Alpha-guaiacene generally has a sweet, earthy, woody, balsamic, spicy aroma.

As used herein, the term "gurenene" or "alpha-gurenene" refers to a compound having the following structural formula:

Alpha-gurenene is generally characterized by a woody, balsamic odor. Alpha-gurene is used in cosmetics and perfumes.

As used herein, the term "exelin" refers to a compound having the following structural formula:

Degurin is commonly found in Herniaria glabra, Ayanpanatriplinervis, and in Prunus species (P. mahaleb, P. pensylvanica, and Ma's Young (P. maximowiczil)).

As used herein, the term "hexanal" refers to a compound having the following structural formula:

Hexanal is often characterized by a grassy odor. Hexanaldehyde is also called hexanal.

As used herein, the term "hexanoic acid" refers to a compound having the following structural formula:

Caproic acid is usually characterized by a pungent, spicy, sour, fatty, sweaty, rancid cheese smell.

As used herein, the term "alpha-humulene" refers to a compound having the following structural formula:

Alpha-humulene is generally characterized by contributing to the flavor profile of beer. Alpha-humulene is sometimes simply referred to as "humulene" or "caryophyllene," and in the context of this disclosure, the two are used interchangeably.

As used herein, the term "beta-humulene" refers to a compound having the following structural formula:

Beta-humulene is generally characterized by a green aroma.

As used herein, the term "ionol" refers to a compound having the following structural formula:

Ionol is also known as butylated hydroxytoluene (BHT). For the purposes of this disclosure, "ionol" also refers to 3-oxo-alpha-ionol and/or beta-ionol in pure and/or mixtures in any ratio. Ionols are generally characterized by sweet, woody, herbal, fruity, floral, tropical and berry aromas.

As used herein, the term "ionone" refers to either or both of alpha-ionone and/or beta-ionone, either in pure form or as a mixture in any ratio.

Alpha-ionone refers to the following structural formula:

Beta-ionone refers to the following structural formula:

Alpha-ionone and beta-ionone as a mixture have an aroma similar to violet flower.

As used herein, the term "beetle dienol" refers to a compound having the following structural formula:

Beetle dienol is generally characterized by a balsamic, rosin aroma.

As used herein, the term "isoamyl acetate" refers to a compound having the following structural formula:

Isoamyl acetate is generally characterized by an odor similar to that of bananas and pears.

As used herein, the term "isoamyl alcohol" refers to a compound having the following structural formula:

Isoamyl alcohol is often characterized by a pungent, fermented, fusel, alcohol-like aroma with fruity, banana, and molasses notes. Isoamyl alcohol is used as a fragrance and essence.

As used herein, the term "isoamyl formate" refers to a compound having the following structural formula:

Isoamyl formate is generally characterized by winey, dry, earthy, fruity, green, plum and blackcurrant aromas.

As used herein, the term "isobornyl" refers to a compound having the following structural formula:

Isoborneol is generally characterized by a camphor, sweet and musty odor.

As used herein, the term "isomyrcenol" refers to a compound having the following structural formula:

Isomyrcenol is generally characterized by a fresh, floral, lime-like odor. Isomyrcenol is used in the chemical communication system of beetles.

As used herein, the term "isopulegol" refers to a compound having the following structural formula:

Isopulegol is generally characterized by a moderately intense odor, ie minty, cooling and bittersweet. In the context of this disclosure, "isopulegol" may also refer to any number of isomeric forms.

As used herein, the term "isovaleric acid" refers to a compound having the following structural formula:

Isovaleric acid is often characterized by a strong, pungent, sour and sweaty cheese odor. Isovaleric acid is also known as 3-methylbutyric acid.

As used herein, the term "isoprene" refers to a compound having the following structural formula:

Isoprene is generally characterized as the building block of many other terpenes.

As used herein, the term "caffeicol" refers to a compound having the following structural formula:

As used herein, the term "lavandidol" refers to the R and S enantiomers in pure form or a mixture in any ratio, having the following structural formula:

Lavender alcohol is commonly found in lavender essential oil.

As used herein, the term "limonene" refers to a terpene having the following structural formula:

Limonene is often characterized by an odor similar to oranges and other citrus fruits. In the context of the present disclosure, the term "limonene" includes all possible enantiomers and isomers of compounds as individual compounds or as racemic mixtures.

As used herein, the term "gamma-linolenic acid" refers to a compound having the following structural formula:

Gamma-linolenic acid is generally characterized as an unsaturated fatty acid mainly found in vegetable oils.

As used herein, the term "linalool" refers to a terpene having the following structural formula:

Linalool has two known enantiomeric forms. The (S)-(+)-linalool is generally characterized as sweet and floral, while the (R)-form is more woody and lavender. In the context of this disclosure, "linalool" refers to either one of the enantiomers or a racemic mixture of both.

As used herein, the term "longifene" refers to compounds having (+) and (-) enantiomers. The (+) enantiomer refers to the following structural formula:

In the context of the present disclosure, the term "longifolene" refers to its (+) and/or (-) enantiomers in pure form or as a mixture in any ratio. Longifene is generally characterized by a sweet, woody, rosy, medicinal, fir needle-like odor.

As used herein, the term "alpha-longifolene" refers to a compound having the following structural formula:

Alpha-longifole is generally characterized by a rosin odor.

As used herein, the term "lycopene" refers to a compound having the following structural formula:

Lycopene is usually characterized by its red color.

As used herein, the term "luteolin" refers to a compound having the following structural formula:

Luteolin is commonly found in leaves, fruit peel, bark, clover and ragweed pollen.

As used herein, the term "menthol" refers to a compound having the following structural formula:

Menthol is generally characterized as having a cooling, minty, peppermint aroma and flavor. Menthol is obtained from peppermint, peppermint, or other peppermint oils.

As used herein, the term "methyl butyrate" refers to a compound having the following structural formula:

Methyl butyrate is often characterized by a sulfur-containing odor.

As used herein, the term "3-mercapto-2-methylpentanal" refers to a compound having the following structural formula:

3-Mercapto-2-methylpentanal is generally characterized by a sulfur-containing, garlicky, garlicky odor.

As used herein, the term "3-mercapto-2-methylpentanol" refers to a compound having the following structural formula:

3-Mercapto-2-methylpentanol is generally characterized by a very strong, sulfur-containing, onion-type aroma.

As used herein, the term "thiol" refers to an organosulfur compound containing a carbon-bonded sulfhydryl group. Mercaptans are often characterized as the main odor component added to help detect natural gas (which is odorless in its pure form), and the "smell of natural gas" is due to the odor of mercaptans used as odorants. Mercaptans are also known as thiols.

As used herein, the term "beta-mercaptoethanol" refers to a compound having the following structural formula:

Beta-mercaptoethanol is generally characterized by a very strong and persistent sulfurous aroma.

As used herein, the term "thioglycolic acid" refers to a compound having the following structural formula:

Thioglycolic acid is generally characterized by being ugly, sharp, pungent, smelly and durable. Mercaptoacetic acid is also known as thioglycolic acid.

As used herein, the term "allyl thiol" refers to a compound having the following structural formula:

Allyl mercaptans are generally characterized by a strong sulfurous and garlicky aroma.

As used herein, the term "benzylthiol" refers to a compound having the following structural formula:

Benzyl mercaptans are generally characterized by a strong, sharp, garlicky, sulfurous, onion, garlic and horseradish aroma.

As used herein, the term "butylthiol" refers to a compound having the following _{formula C4H10S} . In one embodiment, the butyl mercaptan has the following structural formula:

In one embodiment, the butyl mercaptan has the following structural formula:

Butyl mercaptan is often characterized by a very strong odor, commonly referred to as a "skunk" odor.

As used herein, the term "methylthiol" refers to a compound having the following structural formula:

Methyl mercaptan is often characterized by a very strong, sulfurous, decomposed kale, skunk odor. Methyl mercaptan is also known as methanethiol.

As used herein, the term "furfuryl thiol" refers to a compound having the following structural formula:

Furfuryl mercaptan is generally characterized by a very strong, oily, fatty, sulfurous, skunky odor.

As used herein, the term "ethanedithiol" refers to a compound having the following structural formula:

Ethanethiol is generally characterized by a very strong, sulphurous, skunk odor.

As used herein, the term "propylthiol" refers to a compound having the following structural formula:

Propyl mercaptans are generally characterized by a high intensity, garlic, natural gas, sweet onion, cabbage odor. Propylthiol is also known as propanethiol.

As used herein, the term "thiophenemethylthiol" refers to a compound having the following structural formula:

Thienomethyl mercaptan is generally characterized by a strong roasted coffee, fishy smell. Thienomethyl mercaptan is used as a flavoring agent to imitate the flavor of coffee.

As used herein, the term "methyl salicylate" refers to a compound having the following structural formula:

Methyl salicylate is generally characterized by a strong, distinct wintergreen aroma. Methyl salicylate is used as a fragrance, food and beverage agent.

As used herein, the term "methylbutenol" refers to a compound having the following structural formula:

Methylbutenol is usually characterized by a very strong malt herbal aroma. Methylbutenol is released from twisted-leaf pine in high concentrations.

As used herein, the term "methyl 2-methylvalerate" refers to a carboxylic acid having the following structural formula:

Methyl 2-methylvalerate is generally characterized by fruity, sweet, berry, pineapple, apple, banana, green melon and tropical aromas.

As used herein, the term "methyl thiobutyrate" refers to a compound having the following structural formula:

Methyl thiobutyrate is often characterized as a flavoring and food agent.

As used herein, the term "beta-myrcene" refers to a terpene having the following structural formula:

Beta-myrcene is generally characterized by an earthy, fruity clove-like odor. Beta-myrcene is also known as "myrcene".

As used herein, the term "γ-Iranolene" refers to a compound having the following structural formula:

Gamma-Ilanolene is generally characterized by herbal, woody, and spicy aromas.

As used herein, the term "Nepetalactone" refers to a compound having the following structural formula:

Nepetalactone is often characterized by a valerian odor. Nepetalactone is also one of the main attractants and stimulants in catnip, and when inhaled, it can identify wild play behavior in many cats.

As used herein, the term "nerol" refers to a compound having the following structural formula:

Nerol is often characterized as a fragrance ingredient in cosmetics and as a flavoring agent.

As used herein, the term "nerolidol" refers to a compound having the following structural formula or any mixture:

or Nerolidol is generally characterized by a woody aroma, similar to that of fresh bark. In the context of this disclosure, the term "nerolidol" refers to either or both of the cis and trans isomers.

As used herein, the term "neryl acetate" refers to a compound having the following structural formula:

Neryl acetate is generally characterized by a floral and fruity aroma.

As used herein, the term "nonanal" refers to a compound having the following structural formula:

Nonanal is often characterized by a soapy, citrus odor. Nonanal is an ingredient in perfumes, although it is also present in several natural oils. Nonanaldehyde is also called nonanal.

As used herein, the term "nonanoic acid" refers to a carboxylic acid having the following structural formula:

Non-pelagic acid is often characterized by an unpleasant, rancid, waxy, cloudy, and cheesy aroma.

As used herein, the term "octene" refers to a compound having one of the following isomeric forms:

In the context of this disclosure, octene refers to any isomer in single pure form or a mixture in any ratio.

As used herein, the term "octanal" refers to a compound having the following structural formula:

Octanal is usually characterized by a very strong waxy, citrus, orange peel aroma.

As used herein, the term "octanoic acid" refers to a compound having the following structural formula:

Caprylic acid is often characterized by a musty, rancid, cheese-like, sweat-like odor. Caprylic acid is used as a cosmetic surfactant and as a flavoring agent in processed cheese. Octanoic acid is also called caprylic acid.

As used herein, the term "p-cymene" refers to a compound having the following structural formula:

In the context of the present disclosure, cymene may refer to para-cymene or any other isomeric form, such as meta-cymene or o-cymene.

As used herein, the term "amyl butyrate" refers to a compound having the following structural formula:

Amyl butyrate is often characterized by an odor reminiscent of pear or apricot.

As used herein, the term "phellandrene" refers to either of two structural formulas:

or Alpha-phellandrene is generally characterized by a citrus, herbal, black pepper-like odor. Beta-phellandrene is generally characterized by a peppermint and slightly citrus odor, with a slight mint-turpentine odor.

As used herein, the term "phenylacetaldehyde" refers to a compound having the following structural formula:

Phenylacetaldehyde is usually characterized by a strong pungent honey-like sweetness and green floral odor. Phenylacetaldehyde is found in buckwheat, chocolate, and many other foods and flowers.

As used herein, the term "phenylethanethiol" refers to a compound of the formula: C8H10S, which contains various isomers.

In the context of this disclosure, phenylethanethiol refers to any isomer as a pure compound and/or any mixture. Phenylethanethiol is generally characterized by a high-intensity odor of rubber.

As used herein, the term "phenylacetic acid" refers to a compound having the following structural formula:

Phenylacetic acid is generally characterized as having a sour, sweet, waxy, civet, honey, rosy, floral aroma, similar to honeysuckle, with chocolate and tobacco notes. Phenylacetic acid is also used in cosmetics for perfuming.

As used herein, the term "phytol" refers to a compound having the following structural formula:

Phytol typically has a mild floral, balsamic, and green tea-type aroma.

As used herein, the term "alpha-pinene" refers to a compound having one of the following structural formulas:

and Alpha-pinene is generally characterized by a pine-like aroma.

As used herein, the term "beta-pinene" refers to a terpene having the following structural formula:

Beta-pinene is generally characterized by a woody green pine-like odor. Beta-pinene is one of the most abundant compounds released by forest trees. Beta-pinene is an isomer of pinene.

As used herein, the term "platyphyllin" refers to a compound having the following structural formula:

Phyllophyllin is generally characterized by antiviral and antitumor properties. Phyllophyllin is also known as celastrol methyl ester celastrol.

As used herein, the term "menthone" refers to a compound having the following structural formula:

Menthone longleaf is generally characterized by an odor similar to peppermint.

As used herein, the term "quercetin" refers to a compound having the following structural formula:

As used herein, the term "retinol" refers to a compound having the following structural formula:

Retinol is usually characterized as a type of vitamin A that can be converted into other types of vitamin A.

As used herein, the term "rutin" refers to a compound having the following structural formula:

Rutin is often characterized as a citrus flavonoid and is found in many plants.

As used herein, the term "hinokene" refers to a compound having the following structural formula:

Sininene is generally characterized by peppery, woody, herbal and spicy pine odors with citrus aromas. Sininene is found in oak, tea tree oil, black pepper, and is the main component of carrot seed oil. In the context of the present disclosure, the term sabinene refers to an enantiomeric form or a mixture in any ratio.

As used herein, the term "sinina hydrate" refers to a compound having the following structural formula:

Cypressene hydrate is generally characterized by herbal, peppermint, cineole, and terpyridine spicy nuances.

As used herein, the term "cis-sinkyrene hydrate" refers to a compound having the following structural formula.

Cis-Sinkyrene hydrate is generally characterized by a balsamic odor.

As used herein, the term "trans-hinipene hydrate" refers to the following structural formula.

Trans-Sinkyene hydrate is generally characterized by a woody, balsamic odor.

As used herein, the term "crocin" refers to a compound having the following structural formula:

Scrocin is often characterized as the component primarily responsible for the aroma of saffron.

As used herein, the term "alpha-epidronene" refers to a compound having the following structural formula:

Alpha-epidronene is usually characterized by a pronounced amber odor. Alpha-epidronene is one of the main components of celery seed oil.

As used herein, the term "alpha-citronal" refers to a compound having the following structural formula:

Alpha-sweet neral is usually characterized by a citrus orange, citrus aroma.

As used herein, the term "beta-citronal" refers to a compound having the following structural formula:

Beta-sweet neral is generally characterized by a sweet, fresh, waxy and citrus odor. Beta-citronal is used in perfumes.

As used herein, the term "beta-sitosterol" refers to a compound having the following structural formula:

Beta-sitosterol is found in pecans, avocados, pumpkin seeds, cashews, corn oil, and soybeans.

As used herein, the term "squalene" refers to a compound having the following structural formula:

Squalene is generally characterized as playing an important role in the synthesis of plant and animal sterols.

As used herein, the term "taxadiene" refers to a compound having the following structural formula:

Taxadiene is an intermediate in the synthesis of paclitaxel.

As used herein, the term "terpine" refers to a compound having the following structural formula:

As used herein, the term "terpineol" refers to a compound having the following structural formula:

In the context of the present disclosure, terpineol includes any isomeric form, whether a single form or a mixture in any ratio. Terpineol is widely used in the perfume industry. In the context of this disclosure, terpineol refers to any and all isomeric forms, alpha, beta, gamma, etc., in any ratio or combination,

As used herein, the term "terpinen-4-ol" refers to an isomer of terpineol, which has the following structural formula:

Terpinen-4-ols are generally characterized by herbal, peppery, woody odors and are used in commercial spices. Terpinen-4-ol is considered to be the main active ingredient of tea tree oil.

As used herein, the term "alpha-terpinene" refers to a compound having the following structural formula:

Alpha-terpinene is generally characterized by a lemon-citrus aroma. Alpha-terpinene was isolated from cardamom and marjoram oils.

As used herein, the term "gamma-terpinene" refers to a compound having the following structural formula:

Gamma-terpinene is generally characterized by a herbal, citrus-sweet aroma.

As used herein, the term "terpinene" or "delta-terpinene" refers to a compound having the following structural formula:

Terpinolene is often characterized by a herbal aroma. The taste of terpinolene has been described as sweet, woody, lemony and limey.

As used herein, the term "thiophenol" refers to a compound having the following structural formula:

Thiophenols are often characterized by a sulfur-containing odor.

As used herein, the term "thujone" refers to a compound having one of the following structural formulas:

or In the context of the present disclosure, the term "thujone" refers to any isomeric form in pure form or as a mixture in any ratio. Thujone is generally characterized by a menthol-like odor.

As used herein, the term "thymol" refers to a compound having the following structural formula:

Thymol is usually found in the oil of thyme.

As used herein, the term "alpha-tocopherol" refers to a compound having the following structural formula:

Alpha-tocopherol is generally characterized by a very mild, slightly vegetable oil-like odor.

As used herein, the term "coumarone undecanone" refers to a compound having the following structural formula:

Coumaric undecanones are generally characterized by sweet, spicy, balsamic and coumarous woody tobacco aromas.

As used herein, the term "undecanal" refers to an aldehyde having the following structural formula:

Undecal is usually characterized by a soapy, aldehyde-like, waxy and slightly effervescent orange citrus odor with a watermelon, pineapple and coriander background. Undecanal is a common ingredient in perfumes.

As used herein, the term "valeraldehyde" or "pentanal" refers to a compound having the following structural formula:

Valeraldehyde is generally characterized by a fermented type, diffusive, toasty, fruity smell with berry nuances. Valeraldehyde is used as a flavoring agent and has a wine-like, fermented, toasty, cocoa flavor with a chocolaty tinge.

As used herein, the term "o-tert-butylcyclohexyl acetate" refers to a cyclic ether having the following structural formula:

Ortho-tert-butylcyclohexyl acetate is generally characterized by an earthy, fruity, green, herbaceous, old sawn wood odor of medium intensity. o-tert-butylcyclohexyl acetate is used in perfumes and cosmetics.

As used herein, the term "alpha-ilanene" refers to a compound having the following structural formula:

Alpha-ilanene is generally characterized by a spicy, fruity aroma. Alpha-ylangene is a natural substance commonly found in wine and emitted by some plants.

As used herein, the term "umbelliferone" refers to a compound having the following structural formula:

As used herein, the term "vanillin" refers to a compound having the following structural formula:

Vanillin is generally characterized by a pleasant sweet aroma and characteristic vanilla flavor.

Disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid and a first purified terpene. In one embodiment, the first purified cannabinoid and the first purified terpene are present in non-naturally occurring concentrations. In one embodiment, the first purified cannabinoid and the first purified terpene are present in non-naturally occurring ratios. In one embodiment, the compositions disclosed herein provide specific benefits of a previously unavailable naturally occurring cannabinoid and/or terpene profile, such as in plants, harvested flowers, extracts, or conventional products derived therefrom those found.

In one embodiment, the combination of the first purified cannabinoid and the first purified terpene provides a synergistic effect on mammalian cell receptors such as G protein coupled receptors. In one embodiment, the receptor is CB1. In one embodiment, the receptor is CB2. In one embodiment, the receptor is GPR55. In one embodiment, the receptor is 5HT-1A. In one embodiment, the receptor is 5HT-2A. In one embodiment, the receptor is TRPV1. In one embodiment, the receptor is an opioid receptor, eg, a mu-opioid receptor.

Disclosed herein is a composition comprising:

First purified cannabinoid selected from THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV or CBLVA; and

A first purified terpene selected from the group consisting of limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha-bisabol Alcohol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinene, menthone, camphene or geraniol.

In the context of the present disclosure, use of a "combination of a first purified cannabinoid and a first purified terpene" can be accomplished by formulating a homogeneous mixture prior to consumption (eg, combustion, vaporization, inhalation, or ingestion) of the mixture.

In one embodiment, the compositions disclosed herein are combined with a carrier oil.

As used herein, the term "carrier oil" refers to a substance that facilitates administration of the compositions disclosed herein. In one embodiment, the carrier oil is grapeseed oil. In one embodiment, the carrier oil is coconut oil. In one embodiment, the carrier oil is polyethylene glycol.

As used herein, the term "polyethylene glycol" refers to compounds having the following structural formula:

where n is an integer.

Polyethylene glycol is also known as PEG, polyethylene oxide (PEO) and polyoxyethylene (POE).

In one embodiment, the purification components disclosed herein are purposefully selected to achieve the desired effect. In one embodiment, the purposefully selected purified components are then admixed with a carrier oil. In another embodiment, purposely purified components in a carrier oil are combined with a food product. In another embodiment, purposely purified components in a carrier oil are combined with a beverage product. In another embodiment, purposefully purified components in a carrier oil are combined with personal care products, eg, topical creams, soaps, shampoos, and the like. In another embodiment, purposely purified components in a carrier oil are combined with the drug. In further embodiments, purposely purified components in a carrier oil are combined with plant extracts. In another embodiment, purposely purified components in a carrier oil are used with devices such as vaporizers, intravenous drugs, and the like. In another embodiment, purposely purified components in a carrier oil are used in combination with any of the above embodiments.

In one example, certain purified components, such as purified terpenes, can be added to purified or unpurified cannabinoids to produce the compositions disclosed herein at the time of use.

In the context of the present disclosure, the term "use" includes consumption by ingestion or heating and consumption by, for example, combustion or evaporative inhalation.

In one example, certain purified components, such as purified terpenes, can be added to purified or unpurified cannabinoids to produce the compositions disclosed herein at the time of use. In the context of the present disclosure, the term "use" includes consumption by ingestion or heating and consumption by, for example, combustion or evaporative inhalation.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is cymene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is nerol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is nerol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is alpha-piperene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is alpha-piperene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is nerolidol

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is nerolidol

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is nerolidol

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is beta-myrcene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is alpha-caryophyllene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is beta-caryophyllene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is alpha-pinene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is beta-pinene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is alpha-bisabolol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is delta-3-carene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is menthone.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is geraniol.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the first purified terpene comprise 80-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the first purified terpene comprise 85-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the first purified terpene comprise 90-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the first purified terpene comprise 95-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the first purified terpene comprise 99-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene is greater than 100:1, eg, between 100:1 and 500:1.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene is from 100:1 to 10:1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is from 20:1 to 10:1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 10:1 to 1:1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 5:1 to 1:1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 3:1 to 1:1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 1:1 to 1:10.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is from 1:10 to 1:100.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-pinene in a ratio of 300:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-pinene in a ratio of 250:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-pinene in a ratio of 200:1 to 15:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-pinene in a ratio of 150:1 to 30:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-pinene in a ratio of 100:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-pinene in a ratio of 75:1 to 40:1.

In one embodiment, the compositions disclosed herein comprise purified beta-pinene to CBG in a ratio of greater than 2:1.

In one embodiment, the compositions disclosed herein comprise purified beta-pinene to CBG in a ratio of 2:1 to 4:1.

In one embodiment, the compositions disclosed herein comprise purified beta-pinene to CBG in a ratio of 4:1 to 16:1.

In one embodiment, the compositions disclosed herein comprise purified beta-pinene to CBG in a ratio of 16:1 to 32:1.

In one embodiment, the compositions disclosed herein comprise purified beta-pinene to CBG in a ratio of between 32:1 and 64:1.

In one embodiment, the compositions disclosed herein comprise purified beta-pinene to CBG in a ratio of greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 950:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 875:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 750:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 625:1 to 55:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 500:1 to 65:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 350:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified eucalyptol in a ratio of 240:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of greater than 0.625:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of 0.625:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of 50:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of 75:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified cineole to CBG in a ratio of greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 400:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 350:1 to 20:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 300:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 250:1 to 30:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 200:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 150:1 to 40:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 100:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of greater than 1.5:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 1.5:1 to 3:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 3:1 to 9:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 9:1 to 27:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 27:1 to 81:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-humulene to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 950:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 875:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 750:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 625:1 to 55:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 500:1 to 65:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 350:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified linalool in a ratio of 240:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified linalool to CBG in a ratio of greater than 0.625:1.

In one embodiment, the compositions disclosed herein comprise purified linalool to CBG in a ratio of 0.625:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified linalool to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified linalool to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified linalool to CBG in a ratio of 50:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise purified linalool to CBG in a ratio of 75:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified linalool to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 350:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 300:1 to 15:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 250:1 to 20:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 200:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 150:1 to 30:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 100:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified limonene in a ratio of 85:1 to 40:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG greater than 3.5:1.

In one embodiment, the compositions disclosed herein comprise purified limonene to CBG in a ratio of 3.5:1 to 7:1.

In one embodiment, the compositions disclosed herein comprise purified limonene to CBG in a ratio of 7:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG between 25:1 and 50:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified limonene to CBG in a ratio of between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified nerolidol in a ratio of 150:1 to 4:1.

In one embodiment, the compositions disclosed herein comprise THC to purified nerolidol in a ratio of 120:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise THC to purified nerolidol in a ratio of 60:1 to 15:1.

In one embodiment, the compositions disclosed herein comprise THC to purified nerolidol in a ratio of 30:1 to 20:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified nerolidol to CBG greater than 3:1.

In one embodiment, the compositions disclosed herein comprise purified nerolidol to CBG in a ratio of 3:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise purified nerolidol to CBG in a ratio of 10:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified nerolidol to CBG in a ratio of between 25:1 and 50:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified nerolidol to CBG between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified nerolidol to CBG between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified nerolidol to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-caryophyllene in a ratio of 150:1 to 4:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-caryophyllene in a ratio of 120:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-caryophyllene in a ratio of 60:1 to 15:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-caryophyllene in a ratio of 30:1 to 20:1.

In one embodiment, the compositions disclosed herein comprise purified beta-caryophyllene in a ratio of greater than 3:1 to CBG.

In one embodiment, the compositions disclosed herein comprise purified beta-caryophyllene to CBG in a ratio of 3:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise purified beta-caryophyllene to CBG in a ratio of 10:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-caryophyllene to CBG between 25:1 and 50:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-caryophyllene to CBG between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-caryophyllene to CBG between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise purified beta-caryophyllene in a ratio of greater than 100:1 to CBG.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-pinene in a ratio of 300:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-pinene in a ratio of 250:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-pinene in a ratio of 200:1 to 15:1.

In one embodiment, the compositions disclosed herein comprise a ratio of THC to purified alpha-pinene from 150:1 to 30:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-pinene in a ratio of 100:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-pinene in a ratio of 75:1 to 40:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-pinene to CBG in a ratio of greater than 2:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-pinene to CBG in a ratio of 2:1 to 4:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-pinene to CBG in a ratio of 4:1 to 16:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-pinene to CBG in a ratio of 16:1 to 32:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-pinene to CBG in a ratio of between 32:1 and 64:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-pinene to CBG in a ratio of greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 200:1 to 3:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 175:1 to 7.5:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 150:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 125:1 to 12.5:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 100:1 to 15:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 75:1 to 17.5:1.

In one embodiment, the compositions disclosed herein comprise THC to purified beta-myrcene in a ratio of 50:1 to 20:1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene in a ratio of greater than 3:1 to CBG.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene to CBG in a ratio of 3:1 to 10:1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene to CBG in a ratio of 10:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-myrcene to CBG between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene to CBG in a ratio of between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene in a ratio of greater than 100:1 to CBG.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 2,000:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 1,750:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 1,500:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 1250:1 to 125:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 1,000:1 to 150:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 750:1 to 175:1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-terpineol in a ratio of 500:1 to 200:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of greater than 0.3:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of 0.3:1 to 1:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of 0.3:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of 75:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 1,200:1 to 30:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 1,000:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 900:1 to 60:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 750:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 600:1 to 90:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 425:1 to 105:1.

In one embodiment, the compositions disclosed herein comprise THC to purified terpinolene in a ratio of 350:1 to 120:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified terpinolene to CBG greater than 0.5:1.

In one embodiment, the compositions disclosed herein comprise purified terpinolene to CBG in a ratio of 0.5:1 to 1:1.

In one embodiment, the compositions disclosed herein comprise purified terpinolene to CBG in a ratio of 1:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified terpinolene to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified terpinolene to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified terpinolene to CBG in a ratio of 50:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise purified terpinolene to CBG in a ratio of 75:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified terpinolene to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 1,200:1 to 30:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 1,000:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 900:1 to 60:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 750:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 600:1 to 90:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 425:1 to 105:1.

In one embodiment, the compositions disclosed herein comprise THC to purified menthone in a ratio of 350:1 to 120:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of greater than 0.5:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of 0.5:1 to 1:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of 1:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of 50:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of 75:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified menthone to CBG in a ratio of greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 950:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 875:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 750:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 625:1 to 55:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 500:1 to 65:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 350:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified camphene in a ratio of 240:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified camphene to CBG greater than 0.625:1.

In one embodiment, the compositions disclosed herein comprise purified camphene to CBG in a ratio of 0.625:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified camphene to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified camphene to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified camphene to CBG in a ratio of between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified camphene to CBG in a ratio of between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified camphene to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 950:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 875:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 750:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 625:1 to 55:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 500:1 to 65:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 350:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified delta-3-carene in a ratio of 240:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified delta-3-carene to CBG greater than 0.625:1.

In one embodiment, the compositions disclosed herein comprise purified delta-3-carene to CBG in a ratio of 0.625:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified delta-3-carene to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified delta-3-carene to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified delta-3-carene to CBG in a ratio of between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified delta-3-carene to CBG in a ratio of 75:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified delta-3-carene to CBG greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 950:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 875:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 750:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 625:1 to 55:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 500:1 to 65:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 350:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified geraniol in a ratio of 240:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of greater than 0.625:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of 0.625:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of between 5:1 and 25:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of 25:1 to 50:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise purified geraniol to CBG in a ratio of greater than 100:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 950:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 875:1 to 35:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 750:1 to 45:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 625:1 to 55:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 500:1 to 65:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 350:1 to 75:1.

In one embodiment, the compositions disclosed herein comprise THC to purified paracymene in a ratio of 240:1 to 100:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of greater than 0.625:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of 0.625:1 to 5:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of 5:1 to 25:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of between 25:1 and 50:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of between 50:1 and 75:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of between 75:1 and 100:1.

In one embodiment, the compositions disclosed herein comprise purified paracymene to CBG in a ratio of greater than 100:1.

In one embodiment, the combination of the above-mentioned first purified cannabinoid and first purified terpene comprises selected from the group consisting of THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD , CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA , the second purified cannabinoid of CBLV or CBLVA.

Accordingly, disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene in non-naturally occurring concentrations. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene in non-naturally occurring proportions. In one embodiment, the compositions disclosed herein provide specific benefits of previously unobtainable characteristics of naturally occurring cannabinoids, such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is greater than 100:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 100:1:1 to 10:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 20:1:1 to 10:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 10:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 5:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 3:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 1:1:1 to 1:1:10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 1:1:10 to 1:1:100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 100:50:1 to 10:5:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 50:10:1 to 5:2:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 25:15:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 1:1:1 to 1:5:5.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 1:5:5 to 1:25:100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 100:100:1 to 10:10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 20:20:1 to 10:10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 10:10:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 5:5:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 3:3:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 1:1:1 to 1:10:10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the first purified terpene is from 1:10:10 to 1:100:100.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 80-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 85-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 90-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 95-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 99-100% of the total mass of the composition.

In one embodiment, the above-mentioned combination of the first purified cannabinoid and the first purified terpene comprises selected from the group consisting of limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene , alpha-pinene, beta-pinene, alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpine oil A second purified terpene of terpenes, menthone, camphene or geraniol.

Accordingly, disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid, a first purified terpene, and a second purified terpene in non-naturally occurring concentrations. In one embodiment, the first purified cannabinoid, the first purified terpene, and the second purified terpene are present in non-naturally occurring ratios. In one embodiment, the compositions disclosed herein provide specific benefits of previously unavailable naturally occurring cannabinoid characteristics such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is greater than 100:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 100:1:1 to 10:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 20:1:1 to 10:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 10:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 5:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 3:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:1:1 to 1:1:10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:1:10 to 1:1:100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 100:50:1 to 10:5:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 50:10:1 to 5:2:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 25:15:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:1:1 to 1:5:5.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:5:5 to 1:25:100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 100:100:1 to 10:10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 20:20:1 to 10:10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 10:10:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 5:5:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 3:3:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:1:1 to 1:10:10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:10:10 to 1:100:100.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together is 80-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together is 85-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together is 90-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together is 95-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together is 99-100% of the total mass of the composition.

Disclosed herein are novel compositions comprising a combination of a first purified cannabinoid and a second purified cannabinoid. In one embodiment, the compositions disclosed herein are artificial. In one embodiment, the first purified cannabinoid and the second purified cannabinoid are present in non-naturally occurring concentrations. In one embodiment, the first purified cannabinoid and the second purified cannabinoid are present in non-naturally occurring ratios. In one embodiment, the compositions disclosed herein provide specific benefits of previously unavailable naturally occurring cannabinoid characteristics such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment, the combination of the first purified cannabinoid and the second purified cannabinoid provides a synergistic effect on mammalian cell receptors such as G protein coupled receptors. In one embodiment, the receptor is CB1. In one embodiment, the receptor is CB2. In one embodiment, the receptor is GPR55. In one embodiment, the receptor is 5HT-1A. In one embodiment, the receptor is 5HT-2A. In one embodiment, the receptor is TRPV1. In one embodiment, the receptor is an opioid receptor, eg, a mu-opioid receptor.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is greater than 100:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is between 100:1 and 10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is from 20:1 to 10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is from 10:1 to 1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is from 5:1 to 1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is from 3:1 to 1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is from 1:1 to 1:10.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the second purified cannabinoid comprise 80-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the second purified cannabinoid comprise 85-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the second purified cannabinoid comprise 90-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the second purified cannabinoid comprise 95-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid and the second purified cannabinoid comprise 99-100% of the total mass of the composition.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is D8-THC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is THCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is THCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is THCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBD.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is THCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is THCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is THCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBD.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is THCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is THCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBD.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is THCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBD.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBD.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBN and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBN and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBN and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBNA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBNA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBNV and the second purified cannabinoid is CBNVA.

In one embodiment, the above-mentioned combination of the first purified cannabinoid and the second purified cannabinoid comprises selected from the group consisting of THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD , CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA , the third purified cannabinoid of CBLV or CBLVA.

Accordingly, disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid present in non-naturally occurring concentrations. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid in non-naturally occurring proportions. In one embodiment, the compositions disclosed herein provide specific benefits of previously unavailable naturally occurring cannabinoid characteristics such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is greater than 100:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is between 100:1:1 to 10:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 20:1:1 to 10:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 10:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 5:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 3:1:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 1:1:1 to 1:1:10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 1:1:10 to 1:1:100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is between 100:50:1 to 10:5:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 50:10:1 to 5:2:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 25:15:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 1:1:1 to 1:5:5.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 1:5:5 to 1:25:100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 100:100:1 to 10:10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 20:20:1 to 10:10:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 10:10:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 5:5:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 3:3:1 to 1:1:1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 1:1:1 to 1:10:10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid to the third purified cannabinoid is from 1:10:10 to 1:100:100.

Example

The following examples are provided as non-limiting illustrations of the broader disclosure.

Example 1:

The composition was formulated by combining the following components: purified THC (99 g) and purified β-pinene (0.8 g).

Example 2:

The composition was formulated by combining the following components: purified THC (99 g) and purified geraniol (0.5 g).

Example 3:

The composition was formulated by combining the following components: purified THC (99 g) and purified p-cymene (0.5 g).

Example 4:

The composition was formulated by combining the following components: purified THC (99 g) and purified delta-3-carene (0.25 g).

Example 5:

The composition was formulated by combining the following components: purified THC (99 g) and purified camphene (0.375 g).

Example 6:

The composition was formulated by combining the following components: purified THC (99 g) and purified menthone (0.3 g).

Example 7:

The composition was formulated by combining the following components: purified THC (99 g) and purified terpinolene (0.3 g).

Example 8:

The composition was formulated by combining the following components: purified THC (99 g) and purified alpha-terpineol (0.2 g).

Example 9:

The composition was formulated by combining the following components: purified THC (98 g) and purified beta-myrcene (1.25 g).

Example 10:

The composition was formulated by combining the following components: purified THC (99 g) and purified alpha-pinene (0.8 g).

Example 11:

The composition was formulated by combining the following components: purified THC (98 g) and purified beta-caryophyllene (1.5 g).

Example 12:

The composition was formulated by combining the following components: purified THC (98 g) and purified nerolidol (1.5 g).

Example 13:

The composition was formulated by combining the following components: purified THC (97 g) and purified limonene (1.4 g).

Example 14:

The composition was formulated by combining the following components: purified THC (99 g) and purified linalool (0.375 g).

Example 15:

The composition was formulated by combining the following components: purified THC (99 g) and purified β-pinene (0.8 g).

Example 16:

The composition was formulated by combining the following components: purified THC (99 g) and purified eucalyptol (0.5 g).

Example 17:

The composition was formulated by combining the following components: purified THC (99 g) and purified alpha-humulene (0.9 g).

Example 18:

The composition was formulated by combining the following components: purified THC (51 g), purified CBD (10 g), purified CBG (4 g), purified linalool (0.5 g), purified limonene (0.5 g) and purified Alpha-humulene (0.5 g).

Example 19:

The composition was formulated by combining the following components: purified THC (50 g), purified THCV (10 g), purified CBG (4 g), purified CBC (0.2 g), purified β-pinene (2 g), purified β-Caryophyllene (0.5 g), purified limonene (1 g) and purified eucalyptol (0.25 g).

Example 20:

A composition was formulated by combining the following components: purified THC (20 g); purified CBC (10 g); purified CBN (0.2 g); purified THCV (0.6 g); and purified β-pinene (0.8 g) ).

Example 21:

The composition was formulated by combining the following components: purified THC (51 g); purified CBD (0.2 g); purified CBC (0.2 g); purified CBN (0.2 g); purified THCV (0.6 g); purified β-Caryophyllene (1.6 g); and purified α-terpineol (0.16 g).

Example 22:

The composition was formulated by combining the following components: purified THC (51 g), purified β-pinene (1 g), purified α-terpineol (0.1 g) and purified linalool (0.1 g).

Example 23:

The composition was formulated by combining the following components: purified THC (51 g), purified beta-pinene (1 g), purified alpha-terpineol (0.1 g), purified linalool (0.1 g) and polyethylene Diol (25g).

Example 24:

The composition was formulated by combining the following components: purified THC (51 g); purified CBD (0.2 g); purified CBC (0.2 g); purified CBN (0.2 g); purified THCV (0.6 g); purified β-Caryophyllene (1 g); and purified linalool (0.1 g).

Example 25:

The composition was formulated by combining the following components: purified THC (51 g), purified alpha-pinene (1.6 g) and purified linalool (0.25 g).

Example 26:

The composition was formulated by combining the following components: purified THC (51 g), purified alpha-pinene (1.6 g), purified linalool (0.25 g) and purified alpha-humulene (0.6 g).

Example 27:

A composition was formulated by combining the following components: purified THC (51 g), purified linalool (0.5 g), purified alpha-pinene (0.75 g) and purified eucalyptol (0.75 g).

Example 28:

A composition was formulated by combining the following components: purified THC (51 g), purified linalool (0.5 g), purified alpha-pinene (0.75 g), purified eucalyptol (0.75 g) and purified neroli Tertiary alcohol (1.5 g).

Example 29:

A composition was formulated by combining the following components: purified THC (51 g), purified linalool (0.5 g), purified alpha-pinene (1.6 g), purified eucalyptol (0.75 g) and polyethylene glycol (25g).

Example 30:

A composition was formulated by combining the following components: purified THC (51 g), purified linalool (0.5 g), purified alpha-pinene (1.6 g), purified eucalyptol (0.75 g), purified terpine Oleene (0.25g) and polyethylene glycol (25g).

Example 31:

A composition was formulated by combining the following components: purified THC (51 g), purified beta-caryophyllene (1 g), purified alpha-humulene (1 g) and polyethylene glycol (25 g).

Example 32:

A composition was formulated by combining the following components: purified THC (51 g), purified β-caryophyllene (1 g), purified α-humulene (2 g) and polyethylene glycol (25 g).

Example 33:

A composition was formulated by combining the following components: purified THC (51 g), purified β-caryophyllene (2 g), purified α-humulene (2 g) and polyethylene glycol (25 g).

Example 34:

A composition was formulated by combining the following components: purified THC (75 g) and purified THCV (5 g).

Example 35:

A composition was formulated by combining the following components: purified THC (50 g) and purified CBD (10 g).

Example 36:

A composition was formulated by combining the following components: purified THC (50 g) and purified CBG (5 g).

Example 37:

A composition was formulated by combining the following components: purified THC (75 g) and purified CBC (15 g).

Example 38:

A composition was formulated by combining the following components: purified THC (75 g) and purified CBN (10 g).

Example 39:

A composition was formulated by combining the following components: purified CBD (50 g) and purified alpha-bisabolol (50 g).

Example 40:

A composition was formulated by combining the following components: purified CBC (50 g) and purified alpha-bisabolol (50 g).

Example 41:

A composition was formulated by combining the following components: purified CBG (50 g) and purified alpha-bisabolol (50 g).

Example 42:

A composition was formulated by combining the following components: purified CBD (50 g), purified CBC (50 g) and purified alpha-bisabolol (50 g).

Example 43:

A composition was formulated by combining the following components: purified CBD (50 g), purified CBG (50 g) and purified alpha-bisabolol (50 g).

Example 44:

A composition was formulated by combining the following components: purified CBC (50 g), purified CBG (50 g) and purified CBD (50 g).

Example 45:

A composition was formulated by combining the following components: purified CBC (50 g), purified CBG (50 g) and purified CBN (50 g).

Example 46:

The clinical effect of terpene concentrations was measured by comparing the difference in responses measured between (a) the administration of purified cannabinoids alone and (b) the same purified cannabinoids administered with purified terpenes. Each of the following variables was systematically assessed: cannabinoid compounds present; terpene compounds present; and their absolute and relative concentrations.

In each observational study, each participant was administered a formulation with a specific chemical composition according to the guidelines above. Subjective perceptions were scored based on the Visual Analogue Scale (VAS) in web-based survey questions 60 minutes after the subjects began smoking the samples. Each VAS question asked subjects to click on a horizontal bar at a location that reflected how much they felt, as described by adjectives located at either end of the bar. Clicking on the left end of the bar returns a score of zero, while clicking on the right end returns a score of 10. The "unipolar" question asked subjects to report the intensity of a unique sensation on a scale of zero (not at all) to 10 (extreme) (Baudel reference). "Bipolar" questions are also scored on a scale of 0 to 10. For bipolar questions, clicking in the middle of the bar (a score of 5) means that any given subject reports neutrality with respect to adjectives located at either end of the bar.

The subjective perception scores reported for each VAS survey question were averaged and the averages were compared between the base oil and the low and high terpene enriched samples. The small sample sizes in these experiments yielded suggestive explanations for the sensations elicited by terpene enrichment. Therefore, the most significant perceptions elicited by terpene enrichment were determined according to conservative criteria: 1) terpene enrichment moved from zero to a high percentage as the mean score trended towards a given VAS adjective, and 2) when the mean score changed by at least At 50%, they tend to go from low to high.

The table below illustrates how clinical results were organized to compare trends in specific perceptions when terpene enrichment was investigated.

These examples are non-limiting and serve only to illustrate possible embodiments of the formulations disclosed herein.

While this invention has been described with reference to various exemplary embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of this invention. Those skilled in the art will recognize that various modifications may be made to the exemplary embodiments without departing from the scope of the present invention.

Furthermore, it should be understood that the various features and/or characteristics of the various embodiments herein may be combined with each other. Accordingly, it should be understood that various modifications may be made to the illustrative embodiments, and other arrangements may be devised without departing from the scope of the present invention.

Furthermore, other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. The specification and examples are intended to be regarded as exemplary only, with the scope and spirit being indicated by the claims.

Finally, it should be noted that, as used in this specification and the appended claims, the singular forms "a (a)," "an (an)," and "the (the)" include plural referents unless expressly stated otherwise. limited to a referent and vice versa. As used herein, the terms "include" or "comprising" and grammatical variants thereof are intended to be non-limiting, such that the recitation of one or more items does not preclude alternatives or additions to the referenced items other similar projects.

Claims (16)

1. A composition, comprising:

A first purified cannabinoid; and

A compound selected from the group consisting of a second purified cannabinoid; or a first purified terpene.

2. The composition of claim 1, comprising a first purified terpene.

3. the composition of claim 2, wherein the first purified terpene is selected from the group consisting of: 7, 8-dihydro- α -ionone, 7, 8-dihydro- β -ionone, acetylanisole, acetic acid, acetylcedrene, anethole, anisole, benzaldehyde, bergamotene (α -cis-bergamotene) (α -trans-bergamotene), bisabolol (β -bisabolol), α -bisabolol, borneol, bornyl acetate, butyric acid, juniperbene terpene (α -juniperbene) (λ -juniperbene), cafestol, caffeic acid, camphene, camphor, capsaicin, carene (δ -3-carene), humulene, carvacrol, dextrocarvone, levo-carvone, α -caryophyllene, β -caryophyllene, caryophyllene oxide, cedrene (α -cedrene) (β -cedrene), epoxycedrane (α -epoxycedrane), cedrol, cedrene, chlorogenic acid, cinnamaldehyde, α -amyl-cinnamaldehyde, α -hexyl-cinnamaldehyde, cinnamic acid, cinnamyl alcohol, citronellal, citronellol, cryptopine, curcumene (α -curcumene) (γ -curcumene), decanal, dehydroemethol, diallyl disulfide, dihydroactinidiolide, dimethyl disulfide, eicosane, elemene (β -elemene), artemisinine, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol/1, 8-cineol, eucalyptol (α -cineol) (β -cineol) (γ -cineol), eugenol, euphadienol, farnesene, farnesol (β -fenchyl), fenchyl, geraniol, geranyl acetate, germacrene B, guaiazulene-1 (10), 11-diene, guaiacol, guaiene (α -guaiene), gulene (α -gulinene), deanterazine, hexanal, hexanoic acid, humulene (α -humulene) (β -humulene), ionol (3-oxo- α -ionol) (β -ionol), ionone (α -ionone) (β -ionone), scolecanol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomyrcenol, isopulegol, isovaleric acid, isoprene, stigmatol, lavender alcohol, limonene, γ -linolenic acid, linalool, longifolene, α -longifolene, lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, mercaptan, beta-mercaptoethanol, thioglycolic acid, allyl mercaptan, benzyl mercaptan, butyl mercaptan, ethyl mercaptan, methyl mercaptan, furfuryl mercaptan, ethanedithiol, propyl mercaptan, thienylmethyl mercaptan, methyl salicylate, methyl butenol, methyl-2-methylpentanoate, methylthiobutyrate, myrcene (beta-myrcene), gamma-menthene, nepetalactone, nerol, nerolidol, nerol acetate, nonanal, nonanoic acid, ocimene, octanal, octanoic acid, p-cymene, amyl butyrate, phellandrene, phenylacetaldehyde, phenethyl mercaptan, phenylacetic acid, phytol, pinene, beta-pinene, propanethiol, patulin, pulegone, quercetin, retinol, rutin, sabinene hydrate, cis-sabinene hydrate, trans-sabinene hydrate, safranal, alpha-apiene, alpha-sinenseal, beta-sitosterol, squalene, taxadiene, terpene diol hydrate, terpineol, 4-terpineol, alpha-terpinene, gamma-terpinene, terpinolene, thiophenol, thujone, thymol, alpha-tocopherol, coumarone undecanone, undecanal, pentanal, o-tert-butylcyclohexyl acetate, alpha-ylacene, umbelliferone, or vanillin.

4. The composition of claim 3, wherein the first purified cannabinoid is selected from the group consisting of: cannabigerolic acid (CBGA), cannabigerolic acid monomethyl ether (CBGAM), Cannabigerol (CBG), cannabigerol monomethyl ether (CBGM), cannabigerolic acid (CBGVA), Cannabigerol (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromenic acid (CBCVA), cannabichromene (CBCV), cannabidiolic acid (CBDA), Cannabidiol (CBD), cannabidiol monomethyl ether (CBDM), cannabidiol-C₄(CBD-C₄) Cannabidivarin diphenolic acid (CBDVA), Cannabidivarin (CBDV), cannabidiol (CBD-C)₁) Tetrahydrocannabinolic acid A (THCA-A), tetrahydrocannabinolic acid B (THCA-B), tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinol (THC), tetrahydrocannabinolic acid C₄(THCA-C₄) Tetrahydrocannabinol C₄(THC-C₄) Tetrahydrocannabinolic acid (THCVA), Tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA-C)₁) Tetrahydrocannabinol (THC-C)₁)，Δ⁷-cis-Isotetrahydrocannabivarin, Δ⁸-tetrahydrocannabinolic acid (Δ)⁸-THCA), cannabinoic acid (CBNDVA), Cannabinodiol (CBNDV), Δ⁸-tetrahydrocannabinol (Δ)⁸-THC)，Δ⁹-tetrahydrocannabinol (Δ)⁹-THC), cannabichromenic acid (CBLA), Cannabichromene (CBL), Cannabigerol (CBLV), cannabigerolic acid a (CBEA-a), cannabigerolic acid B (CBEA-B), Cannabigeropine (CBE), Cannabigeropine (CBEV), cannabigerolic acid (CBEVA), cannabigerolic acid (CBEA), cannabigerolic acid (CBLV), cannabigerolic acid (CBLVA), cannabinolic acid (CBNA), Cannabigerol (CBN), cannabinolic acid (CBNVA), cannabinol monomethyl ether (CBNM), cannabinol-C₄(CBN-C₄) sub-Cannabinol (CBV), cannabinol-C₂(CBN-C₂) Cannabinol (CBN-C)₁) Large, largeCannabidiol (CBND), cannabidiolic acid (CBNDA), Cannabidivarin (CBDV), Cannabidiopyranone (CBT), 10-ethoxy-9-hydroxy-Delta^6a-tetrahydrocannabinol, 8, 9-dihydroxy-delta^6a(10a)-tetrahydrocannabinol (8, 9-Di-OH-CBT-C)₅) Dihydroxycannabidivarin (CBTV), ethoxy-dihydroxycannabidivarin (CBTVE), Dihydrocannabidivarin (DCBF), Cannabinoids (CBF), cannabichromanone (CBCN), Cannabidicarbocycloalkane (CBT), 10-oxo-Delta^6a(10a)-tetrahydrocannabinol (OTHC), Δ⁹-cis-tetrahydrocannabinol (cis-THC), canabispsol (cbr), 3,4,5, 6-tetrahydro-7-hydroxy- α -2-trimethyl-9-n-propyl-2, 6-methanol-2H-1-benzoxazocin-5-methanol (OH-iso-HHCV), trihydroxy- δ -9-tetrahydrocannabinol (trihoh-THC), kavain, epigallocatechin gallate, dodecane-2E, 4E,8Z, 10Z-tetraenoic acid isobutylamide, and dodecane-2E, 4E-dienoic acid isobutylamide.

5. the composition of claim 4, wherein the first purified cannabinoid is selected from the group consisting of: THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.

6. The composition according to claim 1, wherein the first purified cannabinoid is THC, and the first purified terpene is selected from the group consisting of: limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinolene, pulegone, camphene, or geraniol.

7. the composition of claim 6, comprising a CBG.

8. The composition of claim 3, wherein the first purified terpene is selected from the group consisting of: limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinolene, pulegone, camphene, or geraniol.

9. The composition of claim 1, comprising a second purified cannabinoid.

10. The composition of claim 2, comprising a second purified cannabinoid.

11. The composition of claim 9, comprising a third purified cannabinoid.

12. the composition of claim 2, comprising a second purified terpene.

13. The composition of claim 2, wherein the first purified cannabinoid and the first purified terpene are in a non-naturally occurring ratio.

14. The composition of claim 2, wherein the first purified cannabinoid and the first purified terpene are in a non-naturally occurring concentration.

15. The composition of claim 1, wherein the composition has a purity of greater than 80%.

16. The composition of claim 1, wherein the composition has a purity of greater than 90%.